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Abstract
Purposes: This thesis represents the composition of three different research topics within prostate
cancer radiation therapy. Part I examines the delivery of curative therapy (CTx) in older men
with localized prostate cancer across strata of potential clinical benefit and examines treatment
trends over time. Part II is an institutional retrospective review of patients treated to 75.6 Gy to
the prostate using intensity modulated radiation therapy (IMRT) without the explicit contouring
of the seminal vesicles. Part III is a literature review of adjuvant (ART) and salvage (SRT)
radiation therapy to examine the optimal timing of radiation therapy after radical prostatectomy.
Methods:
In Part I, we used the Surveillance, Epidemiology and End Results (SEER)-Medicare linked
database to identify 64,192 men ages 67-85 with localized prostate cancer diagnosed from 1996
through 2005. We assessed CTx use, defined as either prostatectomy or radiation, across strata of
potential likelihood of clinical benefit. In Part II, patients treated from January 2000 through
January 2007 at our institution for clinically localized prostate cancer using IMRT were identified
and consecutive patients were selected if they had more than 3 years of follow up and received at
least 75.6 Gy. Clinical information was gathered, toxicity was recorded, and biochemical
disease-free survival was calculated. In Part III, pub-med was searched using keywords prostate
cancer and: radiation therapy; adjuvant radiation therapy; salvage radiation therapy; postoperative radiation therapy
Results:
Part I. Among patients with the lowest likelihood of clinical benefit (low risk cancer and LE <5
years), those diagnosed in 2004-2005 were more than twice as likely to receive CTx as those
diagnosed in 1996-1997 (35.3% vs. 16.0%, respectively). Part II.
Two hundred twenty
three (223) eligible patients received primary IMRT for prostate cancer and the median follow up
was 4.4 years. 5-year BDFS for poor, intermediate, and favorable prognostic group patients was
59.0% [95% Confidence Interval (95% CI) 41.8-72.7%], 83.4% [95% CI 72.4-90.4%], and 92.1%
[95% CI 77.4-97.4%], respectively. Acute and late genitourinary and gastrointestinal Grade-3
toxicities were rare and there were no Grade-4 toxicities. Part III. Although there are multiple
randomized trials suggesting that early intervention with ART can improve biochemical diseasefree, metastasis-free and overall survival in patients at high risk of recurrence, a similar level of
evidence does not exist for the use of SRT.
Conclusions:
Part I. Curative therapy for prostate cancer may be increasingly utilized among patients with the
lowest likelihood of clinical benefit. Part II. Dose escalation using IMRT to treat the prostate
without explicit contouring of the seminal vesicles is safe and effective. Part III. We anticipate
the results from randomized clinical trials to answer further questions regarding the comparison
of ART to SRT following biochemical relapse.
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Introduction
This thesis represents the composition of three different research topics within prostate cancer
radiation therapy, and will therefore be presented in three parts. The treatment of prostate cancer
with radiotherapy is changing rapidly, as new technology and new clinical evidence have been
associated with increased numbers of patients being treated with curative therapy. Given the
increasing number of patients diagnosed with prostate cancer and concerns regarding healthcare
costs, the impact of life expectancy and cancer risk on the delivery of curative treatment is
becoming ever more important. Emerging radiation technologies such as intensity modulated
radiation therapy (IMRT) have impacted how we treat patients with the assumption that side
effects are minimized and cancer cure is maximized. Additionally, as new evidence is emerging
regarding the treatment of prostate cancer after surgery, the literature needs to be aggregated for
the benefit of clinicians. Part I of this thesis therefore relates to national outcomes in prostate
cancer curative therapy. Specifically, we examined the temporal trends in the treatment of older
men with localized prostate cancer, and studied the effects of life expectancy and cancer risk on
the receipt of curative therapy. Part II of this thesis concerns the Yale institutional outcomes of
patients treated with intensity modulated radiation therapy (IMRT) for prostate cancer without
explicit contouring of the seminal vesicles. Part III of this thesis represents a literature review of
adjuvant and salvage radiotherapy after prostatectomy. Please refer to the statement of purpose,
specific hypothesis and specific aims of the thesis on pages 11-12 for further details.
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Part I
In 2010, there will be approximately 217,730 incident cases of and 32,050 deaths from
prostate cancer in the U.S., making it the second most common cause of cancer-related death in
American men[1]. As a result of widespread prostate specific antigen (PSA) testing, the majority
of patients are diagnosed with asymptomatic, clinically localized prostate cancer. However, there
are limited data available from randomized trials to help inform treatment management of
patients with localized disease, complicating the decision process and creating significant
variation in treatment use [2].
Both non-cancer and cancer-related clinical factors can affect the potential benefits of
prostate cancer treatment. Estimates of life expectancy (LE) have emerged as important factors
in treatment decision-making, because prostate cancer is an indolent disease and may take many
years before affecting patient health. Hence, treatment of patients with shorter LE may therefore
contribute to additional costs, side effects, complications, and mortality without a commensurate
improvement in quality of life or survival [3-5]. In addition to LE, the benefits of curative therapy
in patients with clinically localized prostate cancer vary substantially according to cancer
characteristics. Conventional wisdom suggests that the more aggressive the cancer, the more
significant the benefit of treatment for prevention of disease progression and recurrence [6-7].
The National Comprehensive Cancer Network (NCCN) Practice Guidelines in Oncology
provides treatment recommendations based on both life expectancy (LE) and tumor
characteristics [8]. The NCCN recommends active surveillance rather than curative therapy for
patients with low-risk prostate cancer who have LE < 10 years. For patients with intermediaterisk prostate cancer and LE ≥ 10 years, radical prostatectomy or radiation therapy should be
recommended. In addition, the guidelines state that for patients opting for expectant management,
2

surveillance may be completed less frequently for men with LE < 10 years as compared to those
with ≥10 years.
Prior analyses have suggested that cancer characteristics as well as age, comorbidity and
sociodemographic characteristics are key factors in treatment selection [2, 9]. However, these
studies are limited in that they do not explicitly assess patients according to both tumor
aggressiveness and underlying health risk, precluding their ability to explain fully how therapies
are utilized in practice. Moreover, treatment options for prostate cancer patients have expanded
considerably in recent years. While these newer modalities, such as IMRT, may be associated
with better clinical outcomes and decreased side effects, many older patients with less aggressive
cancers may not benefit from treatment. These newer treatments are significantly more expensive
than existing alternatives and little is known about how these resources are allocated.
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Part II
As previously mentioned, many of the newer radiation treatment modalities such as
intensity modulated radiation therapy (IMRT) may be associated with better clinical outcomes
and decreased side effects. The escalation of radiation dose above 72 Gy for prostate cancer has
been strongly correlated with improved biochemical disease free survival [10-17] and clinical
outcomes [18-19]. Multiple retrospective and prospective trials have also clarified the risks
associated with dose escalation [13-15, 17, 20-22] , and it appears that even doses up to 81-86.4
Gy are associated with acceptable toxicity [13, 21, 23]. In addition, the utilization of IMRT for
prostate cancer has been shown to allow dose escalation without a significant increase in toxicity
[13, 17, 20, 24-25] potentially above and beyond what is possible with 3D conformal
radiotherapy alone [13].
Nevertheless, prostate IMRT is not standardized, and prescription of prostate dose with
IMRT varies from institution to institution, with some dose prescriptions based on isocentric
dose, maximum point dose within the tumor, or a planning target volume (PTV). Therefore, for
Part II of this thesis, we completed a retrospective institutional study to review clinical outcomes
from patients with prostate cancer treated by a single radiotherapy department using a uniform
radiation technique with dose escalation using IMRT.
The Yale Department of Therapeutic Radiology technique incorporates high doses of
radiation to the prostate, but unlike some other departments, we do not explicitly irradiate the
seminal vesicles, except for the proximal portion that is incidentally included in the PTV
expansion around the prostate. The incorporation of these structures into the treatment volume is
controversial, and there are several reasons why we exclude them, even in the case of patients at
high risk for seminal vesicle invasion [26-29]. 1) Although patient age, Gleason score, clinical
stage, the amount of cancer in biopsy cores from the base of the prostate and pre-treatment PSA
are features that successfully predict the presence of seminal vesicle involvement, we are not
4

aware of any known factors that correlate with the extent of invasion to include in the clinical
target volume (CTV) [30-35]. 2) The seminal vesicles are situated superior and posterior to the
prostate. The tails of the seminal vesicles run posterior–laterally, with their distal ends frequently
sitting adjacent to the anterior rectal wall. Incorporating the seminal vesicles into the CTV
significantly increases the dose to the rectum [28, 36-37]. Therefore, we theorized that the risk
for acute and late toxicity is much reduced by not including the seminal vesicles in the treatment
plan. 3) The majority of research has found that the pattern of invasion from the prostate to the
seminal vesicles is continuous and usually limited to the proximal half of the structures [38].
Without explicitly incorporating the seminal vesicles into the CTV, the base of the seminal
vesicles is often included in the radiation treatment plan anyway, as the irradiated volume is the
outlined prostate plus a volumetric expansion that takes into account microscopic extension,
movement of the prostate, and daily set up error. To our knowledge, our study represents the only
single-institutional report of IMRT for prostate cancer that has not explicitly included any portion
of the seminal vesicles into the CTV.
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Part III
While radical prostatectomy provides excellent control for clinically localized prostate cancer,
approximately one-third of patients undergoing surgery will have positive surgical margins and
another 9% will have seminal vesicle invasion [39-42].Around one-third of patients will also have
extracapsular extension [42].These adverse pathological risk factors, in addition to the Gleason
score and initial PSA level, are independent predictors of biochemical recurrence of cancer.
Indeed, 40%-50% of high-risk patients have a biochemical recurrence after surgery, and many of
those patients eventually develop metastases [43-48]. Currently, the majority of post-surgical
patients without high-risk features are observed for signs of disease progression without active
treatment. However, recently updated randomized trials have shown a very significant benefit to
immediate "adjuvant" radiation therapy (ART) for prostate cancer at high risk of recurrence, such
as pT3 disease [49-51].Controversy surrounds the optimal timing of postoperative radiotherapy,
as well as what to do when prostate cancer recurs months or years after initial prostatectomy, and
whether the risks and morbidity of radiation therapy in the "salvage" setting outweigh the
intended benefits. In Part III of this thesis, we review the evidence for ART from three
randomized clinical trials [49-51] as well as the retrospective evidence for the use of SRT. In
addition, we discuss the technical aspects of treatment, including dose escalation and treatment
target volume, as well as the cost-effectiveness of ART and SRT based upon current available
literature. Although radiation therapy in the post-prostatectomy setting has generally been well
tolerated, we also examine the complication data associated with treatment.
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Statement of purpose, specific hypothesis, and specific aims
Part I
Given the increasing number of treatment candidates and concerns about rising Medicare costs,
efficient allocation of prostate cancer treatment resources will become ever more important [52].
We therefore developed a framework for stratifying patients according to the complementary
domains of cancer risk and LE. We applied this framework to a retrospective study of Medicare
beneficiaries diagnosed with prostate cancer in 1996 through 2005. Specifically, we assessed: 1)
Patient and tumor characteristics associated with receipt of curative therapy; 2) Patterns of
curative therapy use across strata of potential clinical benefit, as defined by tumor aggressiveness
and LE; and 3) Temporal trends in the use of curative therapy across strata of potential clinical
benefit. We hypothesized that on a national scale, our results would suggest increasing utilization
of curative therapy over time, especially among patients with the lowest likelihood of clinical
benefit.
Part II
In patients with prostate cancer, multiple retrospective and randomized trials have
demonstrated that higher dose irradiation of the prostate is safe, with low morbidity, and has been
strongly correlated with improved clinical outcome. This study presents a single institution
retrospective review of patients treated to 75.6 Gy to the prostate using intensity modulated
radiation therapy (IMRT) without the explicit contouring of the seminal vesicles (SV). We
hypothesized that the risk for acute and late toxicity would be reduced by not including the
seminal vesicles in the treatment plan. We also hypothesized that the risk for biochemical disease
free survival would be similar to other studies in the literature.
Part III

7

Several issues surround the use of adjuvant and salvage radiotherapy for post-prostatectomy
patients, and the literature needs to be aggregated for the benefit of clinicians. We therefore
performed a literature review of adjuvant and salvage radiation after prostatectomy.
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Methods
Part I


Ann Raldow, Cary Gross, James Yu, Carolyn Presley, Richa Sarma, Danil Makarov, and
Laura Cramer were involved in study design. Cary Gross is the principal investigator of
Part I of this thesis. Statistical analysis was completed by Laura Cramer. Ann Raldow
took the lead role with writing of the manuscript, with extensive suggestions and help
from other team members mentioned above.

Study Design Overview
In this retrospective study, we determined the use of curative therapy (CTx) across
cancer-risk and LE strata. In addition, we studied the temporal trends of CTx delivery across
these strata from 1996-2005. CTx was defined as prostatectomy or any form of radiation therapy.
We divided the study sample into low- and moderate-risk categories and defined low-risk patients
with LE < 5 years as those least likely to benefit from treatment and moderate-risk patients with
LE ≥ 10 years as those most likely to benefit (Figure 1). This study was approved by the Yale
Human Investigation Committee.
Data Sources
We used the Surveillance, Epidemiology and End Results (SEER)-Medicare linked
database [53]. The SEER program of the National Cancer Institute (NCI) is comprised of 17 highquality cancer registries throughout the U.S. The coverage rate of SEER registries was
approximately 14% and 26% of the U.S. population during 1991-1999 and 2000-2006,
respectively, and the patients included are representative of the U.S. population with respect to
poverty and education [53-55]. For every patient in the database, SEER provides patient
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demographics and tumor characteristics. Community-level demographics and information on
Medicare enrollment are linked from U.S. Census data and Medicare [53].

Inclusion Criteria
We studied patients diagnosed with stage T1 and T2 prostate cancer during the years
1996 through 2005. We excluded patients with missing grade, missing stage and those with prior
malignancy or a second primary tumor diagnosed within a year of their prostate cancer diagnosis.
To ensure completeness of the data, we excluded patients who did not have full Medicare Parts A
and B coverage or those enrolled in a health maintenance organization within a window 2 years
prior to diagnosis through 9 months after diagnosis. Because Medicare benefits begin at age 65, it
was necessary to limit the sample to patients at least 67-years-old at diagnosis in order to allow
for this assessment period. Patients were also excluded if they were over the age of 85 years at
diagnosis, died within one month of diagnosis or if the reporting source of the cancer was a death
certificate or autopsy report. Finally, patients must have had at least one Medicare claim billed
within the 2- year window prior to diagnosis through 9 months after. The resulting study sample
contained 64,192 patients (Figure 2).

Defining prostate cancer risk
We divided the sample into low- and moderate-risk categories using the NCCN
guidelines, excluding PSA values, which were not recorded in SEER-Medicare prior to 2004.
Low-risk disease was defined as SEER grade 1 or 2 and stage T1 or T2a disease and moderaterisk as SEER grade 3 or 4 or T2b-T2c disease.
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Construction of Variables
The independent variables included in our analysis were age, race, comorbidity, marital
status, year of diagnosis and LE. We categorized age into 4 groups: 67–69, 70–74, 75–79 and 8085; race into white, black, or other; and marital status into married, not married, or unknown. In
order to identify comorbid conditions, we searched inpatient, outpatient, and physician claims
billed between 3 and 24 months prior to Prostate cancer diagnosis. We only used International
Classification of Diseases, 9th revision (ICD-9) codes that appeared on at least one inpatient claim
or two or more outpatient/physician claims. Using the comorbidity categories outlined by
Elixhauser et al. [56], a Cox proportional hazards model was constructed to identify conditions
were significantly associated with survival for a noncancer sample who met the same age and
administrative eligibility criteria as our cancer patients (Appendix 1). The number of conditions a
patient had was then summed to create a comorbidity score, and patients were categorized into 3
groups: 0, 1-2, and ≥3 comorbid conditions. A standard life table approach was used to estimate
LE. A 5% non-cancer sample of age, sex and registry matched Medicare beneficiaries was used
to determine annual mortality rates for each age and comorbidity stratum. We assumed that as
patients moved up to the next age group (i.e., from 67-69 to 70-74), 20% of the surviving patients
advanced to the next comorbidity category. This assumption was founded on clinical judgment
and our investigational results.

Treatment
Prostate cancer treatment was assessed by searching the claims for specific diagnosis,
procedure and revenue center codes (Appendix 2). We defined CTx as receipt of any form of
radiation (including external beam radiation therapy and brachytherapy) or prostatectomy during
the 9 months following diagnosis. Patients were considered to be under watchful waiting if there
11

were no claims billed with the listed codes or if they received primary androgen deprivation
therapy (PADT).

Statistical Analysis
Chi-square tests were used to ascertain bivariate associations between the independent
variables and receipt of CTx. Multivariable logistic regression was used to model the likelihood
of receipt of therapy controlling for the independent variables and SEER registry. Different
models were used for each cancer-risk category. For the analysis of temporal trends, we excluded
the 4 SEER registries that were added in 2000 to reduce bias due to treatment variation across
registries. All analyses were performed using SAS version 9.2 (SAS Institute Inc., Cary, NC,
USA).
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Part II


Ann Raldow, Anne McKeon, Nicole Anderson, and Ayal Aizer helped with data accrual.
Nicole Anderson updated toxicity as well as PSA data on Lawrence and Memorial
Hospital patients. Ann Raldow rewrote the introduction, did background research,
updated the toxicity data on the Yale New Haven Hospital patients, and updated the
tables. James Yu analyzed the data and rewrote and edited the methods, results, and
discussion sections. Richard Peschel and Roy Decker were responsible for reviewing and
approving the project. James Yu is the principal investigator on Part II of this thesis.

Data Collection and Baseline Patient Characteristics
After approval from the Yale Human Investigational Committee, clinical information
from all patients undergoing prostate IMRT administered by the Yale Department of Therapeutic
Radiology at the Yale New Haven Hospital - Hunter Radiation Therapy Center (New Haven, CT)
and Lawrence and Memorial Hospital Department of Radiation Oncology (New London, CT)
from January 2000 through January 2007 was retrospectively collected and compiled using the
TrialDB Clinical Study Data Management System [57]. Patients were categorized into poor,
intermediate, and favorable prognostic groups using the National Comprehensive Cancer
Network (NCCN) Practice Guidelines in Oncology [8].
Clinical information including diagnostic and prognostic information, pre and post
radiation urinary function, patient and physician reported toxicity information, radiation dose,
schedule, and technique, adjuvant therapy and supportive therapy, sexual health, and all recorded
PSA values were abstracted. Any reported toxicity, regardless of whether it was due to a
preexisting condition, was recorded using the National Cancer Institute Common Terminology
Criteria for Adverse Events (CTCAE) Version 3.0 guidelines [58]. Urethral and testicular pain
were recorded as genitourinary toxicities.

13

All consecutive patients treated from 1/1/2000 until 1/31/2007 with localized prostate
cancer, who had received at least 75.6 Gy of radiation, who had not received prior radical
prostatectomy, who were able to be staged clinically, and who had at least 3 years of follow up
PSA values were selected for analysis. Two hundred and twenty three (223) patients were
identified, and the characteristics of these patients are listed in Table 3. Median follow up was
4.4 years (range 3.0 – 7.9 years). Median age at diagnosis was 69 years. Median PSA at
diagnosis was 9.0 ng/mL (range 2.7 – 178 ng/mL, SD 17.0). 63.2% of patients had a clinical
stage of T1c. 32.7% of patients had poor prognostic group disease, 47.5% of patients had
intermediate disease, and 19.7% of patients had favorable prognostic group disease. 97.8% of
patients received 75.6 Gy, and 5 patients (2.2%) received 75.9 – 77.8 Gy.
Pelvic radiotherapy was given to 15 (6.7%) patients with a higher risk of nodal
involvement based on the clinical judgment of the treating physician. Pre-sacral, internal and
external iliac, and obturator nodes were included in the treatment volume for these patients.
Adjuvant hormonal therapy was also given based on the clinical judgment of the treating
physician. Patients with intermediate and high-risk group disease usually received short (6
months) and long-term (1-3 year) hormonal therapy. In addition, patients with significant
obstructive urinary symptoms prior to radiotherapy sometimes received 3 months of androgen
deprivation therapy for cytoreduction and mitigation of acute obstructive urinary toxicity during
radiotherapy. Almost all patients with poor prognostic group disease received adjuvant hormone
therapy (97.3%) compared to less than a third of all patients with favorable group disease
(29.6%).

Statistical Analysis, Definition of Biochemical Disease Free Survival
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Biochemical disease free survival (BDFS) was calculated using the RTOG-ASTRO
Phoenix Consensus definition of the date of biochemical failure [59] (the date when the absolute
PSA reaches a level equal to or greater than 2 ng/ml above the post-radiotherapy nadir). There
was no backdating allowed. Kaplan-Meier curves for BDFS were constructed for each prognostic
group and compared with the log-rank test. Univariable and multivariable biochemical disease
free survival analyses were performed using Cox proportional hazards analysis. Logistic
regressions were performed to estimate the likelihood odds ratios of receiving adjuvant hormonal
therapy or pelvic radiation, based on prognostic group. Statistical analysis was performed using
Stata/SE 9.2 (College Station, TX).

IMRT Technique
A standard dose escalated prostate IMRT protocol was institutionally developed based on
available literature and our own institutional analysis of daily setup error and quality analysis
parameters. All patients underwent 3D CT simulation and treatment planning. The treating
physician contoured the prostate in its entirety. The seminal vesicles were not explicitly
contoured.
Patients were treated in the supine position and were asked to evacuate their bowels prior
to CT simulation and prior to each therapy session. From January 2000 to June 2003, patients
were initially treated with 3D conformal radiation followed by an IMRT boost. These patients
received 66.6 Gy in 37 fractions of 1.8 Gy using a 3D conformal technique, followed by a 9 Gy
boost (in 5 fractions of 1.8 Gy) using IMRT. The 3D conformal radiation was delivered to the
physician-contoured prostate plus a symmetric 1.5 cm margin. The IMRT boost was delivered to
the prostate plus a 1.0 cm symmetric margin in all directions, except for a 0.6 cm posterior
margin at the interface of the prostate and rectum.
15

From June 2003 until January 2007, patients undergoing prostate radiation (without
pelvic radiation) were treated with IMRT through the entire treatment course. The planning
treatment volume (PTV) was defined as the physician contoured prostate plus a symmetric 1.2 cm
margin to encompass microscopic extension and prostate motion. This PTV was treated to 66.6
Gy in 37 daily fractions as the “primary plan”, with dose prescribed to the entire PTV. The
seminal vesicles were not explicitly contoured. As the patients approached the completion of the
initial 66.6 Gy, they received a second CT treatment simulation, and a prostate “cone down” plan
was developed based on this resimulation. The patient then underwent 5 additional fractions of
1.8 Gy to a PTV defined as the contoured prostate plus a 1.0 cm margin in three dimensions, save
for a margin of 0.6 cm at the posterior border with the rectum. There were no scheduled
treatment breaks. Therefore, total dose to the prostate was 75.6 Gy in 42 fractions of 1.8 Gy.
An isocentric five-field technique with 18 MV photons was typically used, using
institutionally standardized normal tissue constraints. Dmax was constrained to 115% of
prescribed dose. Rectal constraint for patients receiving 75.6 Gy was D25 ≤ 70 Gy, with the 50%
isodose line not covering the entire rectum, and the 90% isodose line covering half of the rectum
width on a slice-by-slice inspection of the entire rectum. Deviations from the standard criteria
were allowable when unavoidable and approved by the attending physician. All plans (including
both “primary” and “cone down” plans) were presented at institutional chart rounds for clinical
and dosimetric review.

Quality Assurance
A medical physicist verified all treatment plans with phantom dose measurements prior to
initiation of therapy. Maximum tolerable deviation from planned dose was +/- 3%.
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Part III


Ann Raldow was responsible for literature research and review. She was also the
principal author of the manuscript. James Yu, Sung Kim, and Daniel Hamstra edited and
added to and made significant changes to the manuscript. James Yu is the senior author.

Pub-med was searched using keywords Prostate cancer and: Radiation therapy; Adjuvant
radiation therapy; Salvage radiation therapy; Post-operative radiation therapy
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Results
Part I
The study sample was composed of 64,192 patients. Approximately 61.6% and 38.4% of
the sample was characterized as low- and moderate-risk, respectively. Nearly 85% of the patients
in the study sample were white, 9.3% were black, and the median age was 73 years. Overall,
57.8% of the patients had no comorbid conditions, 33.3% had 1-2 conditions and 8.9% had ≥3
conditions. Diabetes, cardiac arrhythmia and chronic pulmonary disease were the 3 most
prevalent comorbidities.

Curative treatment was delivered to 64.4% of patients with low-risk and 70.0% of
patients with moderate-risk prostate cancer (Table 1). Among the low-risk patients, 24.1% with
LE <5, 50.7% with LE 5 to <10, 74.2% with LE 10 to <15 and 80.7% with LE ≥15 years received
CTx (Figure 3). Among the moderate-risk patients, CTx was administered to 31.6% with LE <5,
60.0% with LE 5 to <10, 79.5% with LE 10 to <15 and 84.5% with LE ≥15 years. Thus,
treatment rates increased with increasing LE. More moderate- than low-risk patients underwent
CTx across all LE groups. Among those with the lowest (low-risk cancer and LE <5 years) and
highest (moderate-risk cancer and LE ≥ 10 years) likelihood of clinical benefit, 24.1% and 80.4%
received CTx, respectively (Table 1).

Age and number of comorbidities were significant determinants of receiving CTx (Tables
1 and 2). Older patients were less likely to be treated (adjusted odds ratio [OR] 0.77; 95% CI
0.73,0.81 for ages 70-74; 0.38; 95% CI 0.36,0.40 for ages 75-79; and 0.11; 95% CI 0.11, 0.12 for
ages 80-85 (Table 2). CTx was more likely to be delivered to patients with fewer comorbidities
(adjusted OR 0.94; 95% CI 0.90, 0.97 for patients with 1-2 comorbidities and 0.57; 95% CI 0.53,
0.60 for patients with ≥3 comorbidities) (Table 2).
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Race and marital status were also significantly associated with receipt of CTx (Tables 1
and 2). Compared to white patients, black patients (adjusted OR 0.64; 95% CI 0.60, 0.68) and
patients of other races (0.64 for other race; 95% CI 0.60, 0.69) were less likely to undergo
treatment (Table 2). Married men were more likely to undergo CTx as compared to unmarried
men (adjusted OR 0.67; 95% CI 0.64, 0.70) (Table 2).
Temporal Trends
The rate of CTx administration increased with time, such that 57.7% and 65.3% of lowrisk and 66.9% and 71.4% of moderate-risk patients received treatment in 1996 and 2005,
respectively (Table 1). The percentage of low- and moderate-risk patients receiving CTx over
time differed by LE category (Figure 4). Patients with the lowest life expectancies (LE <5 years
and LE 5-<10 years) experienced the most substantial increase in CTx rates during the study
period. For instance, the percentage of patients with LE <5 years receiving CTx in 1996-1997
was 16.0% and 21.2% for patients in the low- and moderate-risk categories, respectively. Among
those same groups during 2004-2005, the percentage receiving treatment was 35.3% and 34.2%.
The percentage of those with lowest likelihood of clinical benefit who received treatment more
than doubled during the study period. The proportion of patients with the highest likelihood of
clinical benefit who received CTx increased slightly with time, from 78.8% in 1996-1997 to
81.6% in 2004-2005.
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Part II
Five year BDFS by favorable, intermediate, and poor prognostic groups were 92.1%
[95% Confidence Interval (95% CI) 77.4-97.4%], 83.4% [95% CI 72.4-90.4%], and 59.0% [95%
CI 41.8-72.7%] respectively. By the log-rank test, the Kaplan-Meier curves for poor,
intermediate, and favorable prognostic groups were significantly different (p=0.0012) (Figure 5).
Patients in the poor and intermediate prognostic groups were more likely to receive
adjuvant hormone therapy (Table 4). There were no patients with favorable risk group disease
who received pelvic radiation. Poor prognostic group patients were more likely to have received
pelvic radiation in comparison to intermediate risk group patients (p<0.001).
As expected, in unadjusted univariable Cox proportional hazards analysis (Table 5),
higher Gleason score (p = <0.0001), and poor prognostic group (p=0.0020) were statistically
significant predictors of BDFS. When prognostic group, race, adjuvant hormone therapy, and use
of pelvic radiation were included in a multivariable model, only prognostic group (poor vs.
favorable) achieved statistical significance.
Prostate IMRT with dose escalation was very well tolerated. Acute toxicity from IMRT
was defined as reported toxicity during or within 60 days of the end of radiation therapy (Table
6). Acute grade-3 genitourinary toxicity was 7.6%. Acute grade-3 gastrointestinal toxicity was
rare, occurring in 2.7% of patients. There were no acute grade-4 gastrointestinal or genitourinary
events.
Late toxicity from IMRT was also low (Table 6). Late genitourinary grade-3 toxicity
occurred in 0.45% of patients, and late gastrointestinal grade-3 toxicity occurred in 1.35% of
patients. No patients experienced grade-4 gastrointestinal or genitourinary toxicity.
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Part III
Definition of Salvage Radiotherapy (SRT), and the Distinction Between SRT and Adjuvant RT
(ART)
Generally, "salvage" radiotherapy (SRT) is defined as radiation treatment given for
suspected recurrent malignant disease after a period of observation after prostatectomy. In
contrast, "adjuvant" radiotherapy (ART) refers to treatment directly after prostatectomy in
patients potentially without residual disease and with an undetectable PSA. There are several
important distinctions between SRT and ART: 1) There is a higher likelihood of local residual
disease without distant metastatic disease for patients in whom ART is indicated immediately
post-prostatectomy versus a patient for whom SRT is being considered; 2) The burden of disease
may be higher for SRT vs. ART; and 3) Multiple prospective randomized trials have shown a
benefit to ART, whereas similar evidence is lacking for SRT [49-51] (although a randomized trial
comparing SRT and ART is underway [60].
ART is given for patients at high risk of localized recurrence, generally defined as:
evidence for prostate cancer outside the capsule (extracapsular extension), positive surgical
margins, or seminal vesicle invasion. In contrast, SRT patients can have recurrence years after
RP, and it is often unclear whether the detected PSA represents recurrence locally within the
prostate bed, seminal vesicle remnants, pelvis, or at a distant site. This is obviously important for
RT planning, as delivering RT to the prostate bed is useless if no disease remains locally.
In general, the burden of disease may be different for ART patients versus SRT patients.
Though ART patients can have gross residual disease remaining after radical prostatectomy, they
also often have an undetectable PSA indicative of, at most, microscopic residual disease. In
contrast, all patients who undergo SRT for a biochemical recurrence have either a large enough
burden of disease to cause a detectable PSA, a palpable nodule on digital rectal exam, or gross
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disease detected on CT or MRI. Therefore, some authors suggest that in general, SRT patients
have roughly ten times the disease burden of ART patients [61].
Evidence for ART
Evidence from three randomized ART trials suggests that early treatment can extend
biochemical progression-free, prostate cancer-specific and overall survival (Table 9). The
European Organization for Research and Treatment of Cancer (EORTC) 22911 was a multiinstitutional prospective-controlled trial that randomized 1005 post-prostatectomy patients with
pathological T3 disease or positive surgical margins to a “wait-and-see” arm (n = 503) or an ART
arm (n = 502) [49] In the ART arm, radiation was initiated a median of 90 days after surgery
when patients had recovered with no significant voiding problems. Conventional irradiation with
a target total dose of 60 Gy was delivered over 6 weeks. More specifically, a dose of 50 Gy was
delivered in 25 fractions over 5 weeks to a target volume that encompassed the surgical limits
extending from the seminal vesicles to the apex, and a 10-Gy boost was subsequently delivered in
five fractions over a week to a smaller volume targeting the prostatic bed. Simulation was
performed with an urethrogram and rectal enema and a four-field isocentric box technique was
employed for most of the patients. For the first planning volume, patients were treated with
>9 × 9 cm equivalent square fields, and the majority of patients were treated with a <9 × 9 cm
equivalent square field for the smaller volume. Noteworthy findings in favor of ART included
increased biochemical progression-free survival at 5-years (74.0% vs. 52.6%; P < 0.0001) with a
50% reduction in the risk of biochemical recurrence (Hazard ratio: 0.48 [95% CI: 0.37–0.62]. In
addition, this translated into better clinical progression-free survival (with any clinical failure at
5-years of 8.8% in the ART group as compared to 19.0% in the observation group, p = 0.0009),
the majority of which was due to a decreased rate of cumulative loco-regional failure (with 5-year
rates of 5.4% vs. 15.4%, p = 0.0005). Overall at 5-years this study suggests a number needed to
treat of 2 to prevent biochemical failure and 10 to prevent clinical failure with longer follow-up
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necessary to address survival end-points. However, given that almost half of the men who
relapsed in the observation group were eventually given post-operative radiation this may
decrease the ability to detect differences in metastasis and prostate cancer-specific death. While
the EORTC had initially concluded that all pathologic categories (extracapsular extension,
seminal vesicle invasion, positive margins) benefited from ART, after central pathology review,
they have recently concluded that only patients with positive margins significantly benefit from
ART [62]. Limitations of the study included incomplete central pathological review, the modest
dose of conventional radiation, variations in post-operative PSA nadirs (some men had detectable
PSA post-surgery), as well as different indications for and types of salvage treatment used in the
observation arm.

The Southwest Oncology Group (SWOG) 8794 is a US multi-institutional, prospective
clinical trial that has also provided evidence in favor of using ART in patients with pathologically
advanced prostate cancer. The study randomized 425 men with stage pT3N0M0 disease or
positive surgical margins, to observation (n = 211) or ART arms (n = 214) [50]. This study did
involve a central pathology review, though they note that a significant proportion of patients did
not have this performed. Interestingly, when local and central pathology results were compared,
they were very concordant (95%), unlike in the EORTC study. In the ART arm, radiation was
initiated within 122 days. The radiation dose ranged from 60–64 Gy and was given in 30–32
fractions, with treatment portals including the prostatic fossa and paraprostatic tissues. Median
follow-up was considerable at 12.7 and 12.5 years for the radiation and observation arms,
respectively. In this study the use of ART was associated with a significant reduction in the risk
for PSA recurrence for patients treated with ART, similar to the EORTC study with a 50%
reduction in the risk of PSA recurrence in the ART group (Hazard ratio: 0.43 [95% CI: 0.31–
0.58], p < 0.001). However, with longer follow-up in the SWOG study this improvement in
biochemical control also translated into clinically meaningful end-points including decreased
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clinical recurrence (local or metastatic) or death by 38% (p = 0.001). More importantly the use of
ART was also associated with a 10% improvement in metastasis-free survival at 10 years (71%
vs. 61%, p = 0.016) and an 8% improvement in overall survival (74% vs. 66%, p = 0.023). The
magnitude of benefit was similar for those with or without detectable PSA post-operatively as
well as for those with or without seminal vesicle invasion. Though men benefit from radiation
regardless of whether their post-operative PSA is detectable or not, those with an undetectable
PSA fared better-among the radiation patients; men with an undetectable PSA had a longer
metastasis-free survival than those with a detectable PSA (p = 0.03). And unlike the EORTC
study, all pathologic subgroups significantly benefited in terms of metastases free survival. Like
the EORTC study this results in a number needed to treat for improvement in biochemical control
of approximately 2 with the added knowledge of metastasis and survival benefits observed in 1 in
10 and 1 in 12 men, respectively. These findings are even more compelling when considering that
roughly one-third of patients in the observation group received delayed SRT and that their use of
androgen suppression therapy was almost double that of the adjuvant treatment group.
The third randomized study was the ARO96-02/AUO AP 09/95 trial, which investigated
the role of adjuvant treatment after radical prostatectomy in men with pT3-4N0 disease. Unlike
the EORTC and SWOG studies, however, in order to be eligible for randomization men had to
have an undetectable (<0.1 ng/ml) post-operative PSA [51]. The trial initially enrolled 388
patients. One hundred and ninety-four were assigned to each of the wait-and-see and ART
treatment arms. Of these, 81 patients were excluded because they received hormonal treatment
(3) or did not achieve an undetectable PSA (78). Of the remaining 307 patients, 34 patients on the
RT arm did not receive RT and five patients on the wait-and-see arm received RT. Ultimately,
114 patients underwent ART and 154 men were in the “wait-and-see” arm. In contrast to the two
other randomized ART trials, all patients in the ARO96-02/AUO AP 09/95 study had threedimensional treatment planning. ART was delivered with a three- or four-field technique and was
initiated between 6 and 12 weeks after prostatectomy, lasting a median of 44 days. A target dose
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of 60 Gy was given in 30 fractions to a volume that encompassed the surgical limits from the
seminal vesicles to the apex, with an additional 1-cm margin to include residual microscopic
disease. The follow-up was 5 years. The study, like the EORTC and SWOG studies revealed that
biochemical progression-free survival in the treatment group was significantly better than in the
observation group (72% vs. 54%; HR = 0.53, p = 0.0015) in an intention to treat analysis,
suggesting that patients with an undetectable PSA after surgery still obtain benefit from ART.
Univariate analysis in the ARO96-02/AUO AP 09/95 study showed a treatment benefit in patients
with positive surgical margins, pre-surgical PSA level > 10 ng/mL, or extracapsular extension
without seminal vesicle invasion. There was no subgroup broken down by Gleason score that did
not benefit from ART compared to observation. In multivariate analysis of progression-free
survival, ART (versus observation), pre-operative PSA level of >10, and pT3a/b (vs. pT3c) were
all independent predictors of biochemical outcome.
While all three are commendable studies, the published SWOG data is by far the most
mature, with a median follow-up of over 12 years. As Pound et al. demonstrated, median time
from biochemical recurrence (defined as PSA of at least 0.2 ng/mL) to clinically evident bone
metastasis is about 8 years, with time to biochemical progression (P < .001), Gleason score
(P < .001), and PSA doubling time (P < .001) being factors in determining the probability and
time to progression to metastatic disease [63]. With a follow-up of only 5 years, it is not
surprising that the EORTC and ARO 96-02 trials do not yet demonstrate a metastases or overall
survival advantage although both did demonstrate an approximately 50% reduction in the risk of
biochemical progression. Intriguingly, the hazard ratio for reduction of biochemical failure was
nearly identical across all three studies (0.48, 0.43, and 0.53 for the EORTC, SWOG, and ARO96
studies, respectively), so it may be just a matter of time before this translates to a clinical benefit.
An explanation for the discrepancy in benefit across studies for positive vs. negative margins is
not easily forthcoming. It could have to do with the quality and prevalence of central pathology
review or the variances in patient population or radiation technique.
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Arguments and evidence in favor of SRT
As discussed, recent evidence from these three randomized trials suggests that early
intervention with ART can lengthen biochemical disease-free, metastasis-free and overall
survival in patients with pathologically advanced prostate cancer [49-51]. However, a
disadvantage of routine ART is treating those who would never develop biochemical recurrence
after RP, and unnecessarily exposing an increased number of patients to the side effects of RT. In
addition, there is some evidence that the use of ART may be associated with an increased risk of
toxicity as compared to SRT. A retrospective multi-institutional analysis of 959 men treated with
either adjuvant (19%) or salvage (81%) RT found a low rate of toxicity with a 5-year rate of late
grade 2 or higher genitourinary (GU) toxicity of 12% and a late grade 2 or higher gastrointestinal
(GI) toxicity of 4%. More serious toxicity was rare, with grade 3 GU toxicities in only 1% of all
patients and grade 3 GI toxicities in 0.2% of all patients. Given the small number of events, there
were no predictors that correlated with late GI toxicity, and there was no difference in GI toxicity
between ART and SRT.
However, on multivariate analysis adjuvant RT as compared to both salvage RT (16% vs
11%) and the use of hormonal therapy (19% vs 11%) predicted for increased risks of grade 2 or
greater urinary toxicities [64].Therefore, the use of SRT might protect a significant portion of
men who do not ever require radiotherapy, and in addition, even for those treated with RT may
provide a modest reduction in GU toxicity. However, the cost of a strategy of using SRT in lieu
of ART is that a certain portion of patients may have a lower chance of successful eradication of
their disease with SRT. Whether an equivalent survival benefit can be attained with vigilant
surveillance and early initiation of SRT upon PSA relapse is an unanswered question, and SRT
cannot at present be considered to be equivalent to ART.
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Given this uncertainty, two groups of investigators have attempted to define prognostic
factors that predict the likelihood of obtaining a benefit from SRT. Trock et al. retrospectively
analyzed 635 men, who either received no salvage treatment (n=397), SRT alone (n=160), or
SRT combined with hormonal therapy (n=78) [65].The authors found that 70% of all deaths
during follow-up were from prostate cancer with 10-year rates of prostate cancer–specific
survival of 86% in those treated with salvage RT as compared to 62% without RT. This
represented a 3-fold increase in prostate cancer–specific survival compared to those who received
no salvage treatment (hazard ratio [HR], 0.32; P < .001). The addition of hormonal therapy to
SRT did not improve prostate cancer–specific survival. Also noteworthy was that when SRT was
restricted to the population of patients with pT3 disease who would have been candidates for
ART, the use of salvage RT also provided an OS benefit with 10-year OS of 98% vs 89%.
Interestingly, the prostate cancer–specific survival benefit of SRT was only seen in men
with a PSA doubling time of < 6 months, independent of pathologic stage or Gleason score. This
runs counter to the more commonly held principle that a short doubling time is indicative of
distant disease and, therefore, a lack of benefit to SRT [66]. Moreover, patients who received
SRT more than 2 years from the time of biochemical recurrence did not experience significant
increases in prostate cancer–specific survival.
Further evidence for the use of SRT in prostate cancer comes from a retrospective study
by Stephenson et al, in which they developed a model using a cohort of 1,540 patients [67]. The
authors described several prognostic features that should be considered when predicting improved
biochemical control after SRT: These included PSA level < 2.0 ng/mL at time of SRT, Gleason
score of 7 or less, PSA doubling time > 10 months, positive surgical margins, androgendeprivation therapy before or during SRT, and the absence of lymph node metastasis. It was again
demonstrated that SRT may significantly alter the natural course of the disease, as 60% to 70% of
patients with disease recurrence develop metastasis within 6 years if they do not receive salvage
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therapy [63]. In addition, SRT is recommended to patients with more favorable prognostic
features, as they are thought to be at lower risk for widely disseminated disease [68].
However, the Stephenson study, like the one by Trock et al., suggests that patients with
unfavorable prognostic features may also benefit from SRT if treatment is initiated early after
biochemical recurrence. Indeed the Trock study would suggest that patients with the shortest
doubling time are at the greatest risk for prostate cancer–specific death. Although these patients
may be less likely to have PSA control, given their greater risk of death from prostate cancer if
they do achieve disease control, this translates into a cause specific survival benefit. In contrast,
those with a longer PSA doubling time may be more likely to achieve PSA control with SRT, but
given the lower clinical risk this does not appear to change the risk of prostate cancer–specific
death.
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Discussion
Part I
We found that the use of curative therapy for men with prostate cancer who were in the
lowest likelihood of clinical benefit more than doubled. The NCCN Practice Guidelines in
Oncology provide treatment recommendations based on non-cancer “health status” in addition to
cancer-specific prognostic factors [69]. However, our results suggest that patients may not receive
CTx in accordance with these strata, and that treatments are diffusing into practice in a pattern
that does not correspond to the likelihood of clinical benefit.
Treatment trends indicate that the rates of treatment in both the low- and moderate-risk
categories have increased significantly with time. Compared to baseline rates in 1996-1997, the
treatment of patients with the lowest and highest likelihood of clinical benefit both increased.
While the treatment of those with the lowest likelihood of clinical benefit more than doubled over
the study period, there was a relatively modest increase in the rates for patients with the highest
likelihood of clinical benefit. A recent study by Cooperberg et al. suggested that overtreatment of
low-risk patients decreased from 1990 through 2007, but that undertreatment of high-risk disease
was becoming more worrisome in recent years [2]. However, PADT was included as a
therapeutic option in the prior analysis, so the discrepancy in results may be due to the
documented decrease in PADT utilization after reimbursement changes made by the Medicare
Modernization Act of 2003[70-71].

Our findings highlight two important and potentially problematic patterns of
treatment: possible lack of treatment of patients with the highest likelihood of clinical
benefit and overly aggressive treatment of patients with the lowest likelihood of clinical
benefit. The implication of overtreatment and undertreatment is that clinicians are
choosing to treat clinically localized Prostate cancer patients based on factors external to
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their LE and cancer-risk. We hypothesize that as side effects from CTx lessen through
advances in therapeutic knowledge and new technology, the threshold for acceptable baseline
health and cancer-risk for candidates of CTx is becoming reduced.
While failing to treat a potentially fatal cancer can reflect poor-quality care, aggressive
management of disease that is unlikely to progress may also be inappropriate since it puts patients
at risk for considerable morbidity and adds to cost without bestowing medical benefits [3-5].
Acknowledging that superfluous care is suboptimal, and considering the collective financial and
health burdens that stem from Prostate cancer and its treatment, the reallocation of CTx from
patients in whom it is unnecessary or even harmful to those in whom it is necessary would create
more equitable cancer care and likely improve outcomes for men with Prostate cancer.

At the same time, we recognize that overtreatment and undertreatment will never be
eradicated as long as patients maintain autonomy over their own treatment decisions, as CTx is
highly sensitive to patient preferences [72]. The prediction of LE and cancer progression in its
current state is an imperfect science [73]. When side effects are low, some patients may prefer to
be treated aggressively, as the psychological and physical burden of metastatic cancer can be
devastating. Other patients may chose to forgo treatment, as Prostate cancer is generally
considered to be a more indolent cancer with treatment options including active surveillance. The
optimal rates of over- and under-treatment are difficult to define, but treatment decisions should
correspond to the likelihood of potential clinical benefit as defined by tumor aggressiveness and
LE.

Consistent with other studies, we found that age was a key factor in treatment selection
[73-77]. In a New Mexico Tumor Registry study of patients diagnosed with local stage Prostate
cancer between 1969 and 1982, 14% as compared to only 4% of patients did not receive
definitive treatment for age groups ≥85 and 55-64 years, respectively [73]. Several age-dependent
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factors may explain our results. Older men may elect not to undergo CTx because of lack of
adequate social or emotional support, misinterpretation of presented information, or a feeling of
resignation due to increasing age [78-81]. At the same time, clinicians may be more hesitant to
recommend aggressive therapy to older men due to increased concern about side effects and
mortality. However, age alone should not be the basis for withholding care, especially in
otherwise healthy men with higher-risk clinically localized disease and longer LE.
We also found that married and white patients were more likely to receive CTx as
compared to unmarried and black patients, respectively. The association between marital status
and cancer treatment is well documented and reflects the influence of spousal support on health
maintenance [82]. Our findings with respect to race support a recent study using SEER-Medicare
data from 1992-2002, which found that racial disparities in Prostate cancer patients receiving
definitive treatment were present and did not improve over time [83]. The Council on Ethical and
Judicial Affairs of the American Medical Association has stressed the necessity of practice
guidelines that minimize racial disparities in treatment decisions [84].
Patients with low-risk Prostate cancer and short LE should be considered for active
surveillance and educated regarding its benefits, while the majority of men with moderate-risk
disease and long LE, regardless of age, race, or marital status, should be counseled regarding the
efficacy of therapy with either radiation or surgery.
There are several limitations to our study. Medicare claims may not capture all cancermitigating procedures and comorbid illnesses. Our study population was limited to men aged 67–
85 years, so our findings may not be generalizable to younger men with Prostate cancer. Also,
Medicare beneficiaries and privately-insured patients may not be representative of all older men
diagnosed with Prostate cancer in regards to risk profile and treatment options. In addition,
grading and staging can be subject to intra- and inter-observer variation, affecting the risk
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assignment of patients. Lastly, the Elixhauser Comorbidity Index classifies only 31 possible
comorbidities, of which 25 were included in the analysis. The use of total number of
comorbidities to predict survival may not be optimal because certain comorbidities may have
more significant impact on LE than others. Controlling for other potential unmeasured
confounders such as patient education and income, as well as physician awareness and training,
could potentially increase the validity of our findings.
Strengths of our study include the large number of patients and the relatively
comprehensive nature of Medicare billing claims. Additionally, our sample was drawn from a
large national cohort of patients who were treated by all physician types, including primary care
physicians, urologists, medical oncologists and radiation oncologists. The findings of our study
are relevant from a health policy standpoint as our results reflect national treatment trends over
time and represent the use of public funds, which the government is obliged to spend in the most
effective manner possible. Given the policy to reduce national healthcare expenditures and the
questions surrounding the appropriate treatment of older men with clinically localized Prostate
cancer, this analysis can be used to inform the future allocation of treatment resources.
Conclusion
The receipt of CTx for Prostate cancer is highly correlated with LE. Additionally, being
older, of non-white race, unmarried or having comorbid illness is associated with a lower
likelihood of receiving CTx for Prostate cancer. Compared to baseline rates in 1996-1997, the
treatment of both patients with both the lowest and highest likelihood of clinical benefit has
increased. The geographic allocation of healthcare resources and the impact of new surgical and
radiation technologies on overtreatment and undertreatment are areas in urgent need of study.
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Part II
While increased doses of prostate external beam radiation therapy above 72 Gy have
previously been shown to improve BDFS, this report represents the only single-institutional study
that has not explicitly incorporated the seminal vesicles into the IMRT treatment plan [10-14, 16,
85]. Biochemical disease free survival for our cohort of patients is presented in the context of the
most recent prostate dose escalation trials in Table 6. Both our institutional technique and that of
other institutions show excellent BDFS and toxicity outcomes.
Intermediate prognostic group patients had worse 5-year biochemical disease free
survival in comparison to favorable prognostic group patients though this was not a statistically
significant difference due to an underpowered cohort. During the period of study, our
institutional practice was to treat patients in the intermediate prognostic group with 6 months of
adjuvant hormonal therapy, which has been shown to improve overall survival over standard
radiotherapy alone with doses less than 72 Gy [86]. As follow up of these patients continues, it
will be interesting to see whether this non-statistically significant trend to a difference in
biochemical disease free survival persists and whether it will lead to metastatic disease free
survival and overall survival differences. Biochemical disease free survival has been shown to be
a useful surrogate for clinical disease free survival and overall survival [59] given the long natural
course of most prostate cancers. Based on a higher proportion of metastatic disease among
patients receiving lower doses of radiotherapy as to those with higher doses, Kuban et al. reported
possible future improvement in survival in patients treated to doses as high as 78Gy [15].
In multivariable analysis, poor prognostic group status (compared to favorable) was the
only significant predictor of biochemical disease free survival. At our institution, however,
almost all patients with high risk disease are treated with adjuvant long term hormonal therapy (13 years), in conjunction with IMRT dose escalation. The addition of long term hormonal therapy
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has been definitively shown to significantly improve clinical disease free survival and overall
survival over 70 Gy alone [87].
The improvement in biochemical disease free survival has been made possible without
significant additional toxicity due to improvements in radiotherapy technique allowing the
sparing of local normal tissue, either by 3D conformal technique [13, 15-16, 85, 88-89], proton
therapy [14], or more recently, IMRT [13, 21]. Other authors have reported a low rate of acute
and late gastrointestinal and genitourinary toxicity, and our results are consistent with these
reports, [17, 20] listed in Table 5. In another series, average time to late grade-3+ toxicity after
therapy was 23.1 – 23.2 months [22], and it is therefore unlikely that significant additional
toxicities will develop in our cohort.
Our reported acute grade-3 genitourinary toxicity was slightly higher than some reported
rates, partly as a result of our broader definition of morbidity. Any genitourinary toxicity,
regardless of whether the clinician thought it was due to radiotherapy or was due to a preexisting
condition was reported. In addition, toxicity that was coded in other CTCAE-3 categories such as
pain or infection were counted as genitourinary toxicity if it was due to or pertaining to the
genitourinary system, even though the CTCAE-3 codes pain as a separate category. Nonetheless,
our rates of genitourinary toxicity were still very low and consistent with the reported literature.
Whether acute grade-3 renal / genitourinary toxicity correlates to pretreatment American
Urological Association (AUA) symptom score and other preexisting conditions remains the
subject of further analysis.
Gastrointestinal toxicity was low, with grade-3 acute toxicity of 2.7% and a late grade-3
gastrointestinal toxicity of 1.35%. As noted previously, there were no grade-4 GI or GU
toxicities. This excellent profile was likely due to the careful attention to rectal dose tolerances
and consistent and careful quality analysis performed on each patient plan performed by our
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physics staff. We also did not explicitly contour the seminal vesicles, which allowed for a shorter
segment of rectum to be irradiated during the course of prostate radiotherapy. Although we
theorized that the risk for acute and late toxicity should be much reduced by not including the
seminal vesicles in the treatment plan, similarly excellent toxicity has been obtained while
irradiating a larger portion of seminal vesicles to the same radiation dose (Table 5). Other
investigators have noted that it is still possible to irradiate the entire seminal vesicles using IMRT
and remain under acceptable dose constraints and normal tissue complication probability [90]. A
randomized controlled trial comparing our institutional radiation technique to that of other
institutions is unlikely at this time.
As new technology allows the precise location of the prostate with each radiotherapy
treatment, further prostate dose escalation to 79.2Gy with image guided intensity modulated
radiation therapy (IG-IMRT) is now offered to all patients at our institution. Doses up to 81-86.4
Gy treated with IMRT have been shown to offer low acute toxicity [14, 21, 23].Whether we can
improve on outcomes with the addition of hormonal therapy to dose escalation for the
intermediate and poor prognostic groups remains to be seen. The integration of image guidance
to IMRT has allowed further dose escalation with the relative sparing of normal tissue. This
further dose escalation will hopefully open yet another door to improved patient outcomes and
cure rates.
Conclusion
Prostate dose escalation using IMRT is safe and effective. Durable biochemical disease
free survival remains the subject of further study, but current trends are promising. Moderate
acute genitourinary morbidity is uncommon, and moderate late genitourinary morbidity is rare.
Severe grade-4 gastrointestinal or genitourinary morbidity has not occurred in our cohort of 223
patients. Patients with a poor prognosis will require more aggressive treatment with doses higher
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than 75.6 Gy to the prostate, in combination with hormonal therapy. The optimal combination of
pelvic radiotherapy, further dose escalation, and hormonal therapy for prostate cancer remains the
subject of further investigation. Whether biochemical disease free survival rates will translate
into metastasis free and overall survival remains the subject of further longitudinal study.
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Part III
Current Treatment—Defining the Surgical Bed
Although some authors have reported on the use of low-dose rate [91] or high-dose rate
[92] brachytherapy for the treatment of prostate cancer that has recurred after RP, by far the most
commonly used treatment modality is external beam radiotherapy (EBRT). Therefore, our
discussion will concern EBRT only. External beam salvage radiotherapy typically involves 3D
conformal or Intensity Modulated Radiation Therapy (IMRT) to the prostate bed alone, with
radiation fields designed to treat areas at the highest risk for local recurrence. Radiation therapy
treatment volumes are in principle identical to those used for ART; therefore, lessons from ART
randomized trials and ART consensus statements apply.
The randomized trials mentioned earlier were conducted in the era before the widespread
adoption of 3D conformal or IMRT techniques, and therefore involved 9 × 9 cm or 10 × 10 cm
fields centered around the prostatic fossa [49-51]. However, 3D conformal and IMRT techniques
allow for the targeting of the prostatic fossa, urethrovesical anastamosis, and surrounding tissues
at risk, with relative sparing of the rectum, bladder, and penile bulb. Multiple consensus
guidelines have been created for the definition of the clinical target volume (CTV), most
significantly from the EORTC, RTOG, and RADICALS groups [93-95].
All three consensus groups generally advocate for the treatment of the vesicourethral
anastamosis (VUA) and surrounding periurethral tissue. However, they advocate therapy to
different amounts of additional tissue such as the bladder and seminal vesicle beds. The RTOG
and RADICALS groups recommend defining the VUA using the most inferior visualized urine in
the bladder on sagittal reconstruction, while the EORTC defines the VUA as 15 mm cranial to the
penile bulb. At the level of the pubic symphysis, anteriorly and posteriorly, all three consensus
groups essentially cover the region from the pubic symphysis to the rectum, and laterally the
medial border of the obdurator internus and levator ani muscles. The lateral borders were
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generally the pelvic fascia superior to the pubic symphysis. At the bladder wall, the EORTC has
perhaps the most limited CTV definition, and in contrast to the RTOG and RADICALS groups,
does not advocate for the inclusion of 1.5 cm of posterior bladder and bladder wall. In the
rectovesical /seminal vesicle bed space, the EORTC and RTOG advocate for the coverage of the
seminal vesicle beds if there is pathologic involvement of the seminal vesicles in the surgical
specimen, but to otherwise largely spare the seminal vesicle beds (though they do say to cover
where the base of the seminal vesicles used to reside). Any retained seminal vesicle remnants
should be included if the seminal vesicles were involved pathologically. The superior border in
the rectovesicular space is at or 5 mm above the level of the cut end of the vas deferens or at the
level of the most superior surgical clips. Inferiorly, the RADICALS group recommends placing
the border at 8-12 mm below the vesicourethral anastamosis, but not to include the penile bulb.
There was some concern in the RTOG group that apical tumors could extend into the genitourinal
(GU) diaphragm and inferior urethral sphincter, and this was the reason it was recommended that
the inferior aspect of the CTV extend to a level just above the penile bulb [94].
Separately, Miralbell et al. recommend a cylindrical CTV centered 0.5 cm posterior and 3
mm inferior to the VUA, measuring 4 cm in height and 3 cm in diameter [96]. This volume
considerably spared the rectum, and may represent a way in which to limit radiation-associated
toxicities and improve the quality of life of prostate cancer patients. This CTV recommendation
was based on an MRI series of 60 men, and is consistent with another MRI study showing
recurrences largely around the VUA [97] However, this very VUA-centric volume stands in
contrast to another MRI study which showed more local recurrences in the rectovesicular space
outside of the proposed CTV [98]. Further studies regarding the optimal volume of treatment are
necessary, and it is hoped that information from the RADICALS trial will shed more light.
Minimizing daily set-up error and ensuring reproducible localization of the prostate bed
is a current area of study. Calypso beacon localization has been suggested as a useful tool for
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localization of the prostate bed as has daily portal imaging with implanted gold fiducial markers
[99] or daily cone-beam imaging or kilovoltage imaging [100]. These techniques attempt to
minimize daily setup error and take into account any variation in the location of the VUA
depending on day-to-day differences in rectal volume and bladder distension. A general
consensus on the differential benefit of these techniques has not been found, though most authors
agree that daily localization is important for reducing treatment margins and thus further reducing
radiation to normal tissue.
Dose
The proper radiation dose that delivers a balance of optimal disease control while limiting
side effects is not clear; however, it is thought that the use of increased RT doses may provide
higher chances of cure. Until recently, there were only three retrospective studies with small
sample sizes that showed that doses above 64.8 Gy are beneficial [101-103]. While doses of 78
Gy are used for RT in the definitive setting, doses for ART or SRT are generally lower because it
is assumed that the tumor burden is microscopic [12, 14, 89] and the presence of bladder and
rectum within the prostate resection fossa increases the normal tissues radiated. As noted
previously, randomized ART trials delivered radiation in the range of 60-64 Gy to relatively large
fields [49-51]. The RADICALS trial is testing a dose of 66 Gy in 33 fractions, or 52.5 Gy in 20
fractions [60]. King et al. recommend at least 70 Gy based on a retrospective study showing a
significant dose response between 60 and 70 Gy of radiation to the prostate bed [104].
Specifically, King et al. analyzed 122 patients with pathologically negative lymph nodes with a
median follow-up > 5 years. Thirty-eight patients received a median dose of 60 Gy to the prostate
bed and 84 patients received a median dose of 70 Gy. Sixty-eight patients received four months
of androgen suppression therapy and 72 patients received whole-pelvic RT. The authors observed
a significant dose response from 60 to 70 Gy (25% vs 58% biochemical disease-free survival at 5
years, respectively; P < .0001). On multivariate analysis the two clinical factors that predicted
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improved biochemical-free survival were a pre-RT PSA level of 1 ng/mL (HR 0.28, P <.0001),
and no seminal vesicle involvement (HR 0.44, P = .009). Thus, this study suggests that higher
doses may help increase the likelihood of optimal disease-free survival. The dose of 70 Gy
correlated with an increased dose of 6 Gy required for SRT vs ART, which King et al. argued in a
separate manuscript was due to the additional disease burden carried by SRT patients vs ART
patients [61]. In the absence of evidence that this additional dose causes worse late toxicities in
patients undergoing SRT, a radiation dose in the region of 70 Gy is reasonable [64]. Currently,
the American Society for Therapeutic Radiology and Oncology (ASTRO) advises the use of the
highest dose of radiation that can be delivered with acceptable morbidity (at least 64 Gy at
conventional fractionation) for SRT [105].
Hypofractionated radiotherapy (daily radiation doses of greater than 2 Gy) has been considered
for SRT in a retrospective analysis of 50 patients [106]. Hypofractionated therapy is potentially
desirable due to its shorter overall treatment length and theoretically higher biologically
equivalent dose. Though toxicity and 2-year biochemical control rate appeared equivalent to
published data for standard fractionation, additional follow-up and greater numbers of patients are
needed before widespread adoption of this technique.
Hormone Therapy
The use of hormone therapy in combination with post-operative RT is an area of controversy that
will hopefully be clarified by three randomized trials: 1) The RTOG 96-01 trial, 2) The RTOG
05-34 SSPORT trial, and 3) The RADICALS trial. The RTOG 96-01 trial is a prospective
randomized trial comparing postoperative RT with and without 2 years of bicalutamide 150
mg/day which has completed and should be presented in 2010 [107]. The RTOG 0534 is an
ongoing phase III trial of short-term androgen deprivation with pelvic lymph node or prostate
bed–only radiotherapy (SPPORT) in prostate cancer patients with a rising PSA after RP. This 3-
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arm randomized trial is assessing prostate bed RT vs prostate bed RT with short-term androgen
ablation vs pelvic and prostate RT along with short-term androgen ablation [107]. As noted
previously, the RADICALS trial is a prospective trial with two randomizations.
The first randomization will investigate immediate ART versus delayed SRT at the time of
biochemical recurrence. Patients receiving RT will then be further randomized to RT alone, RT +
6 months of hormones, or RT + 2 years of hormones [60]. Although hormone therapy has been
shown to improve overall survival in combination with EBRT for men with prostate cancer of
intermediate- or high-risk disease, the value of hormone therapy has not yet been proven for men
undergoing either ART or SRT [86-87, 108].
Side Effects and Toxicities Associated With Radiotherapy After Prostatectomy
Radiation treatment is the only potentially curative treatment available for most patients
with biochemical failure after RP. However, some would argue that quality of life (QOL) is as
important as survival. Despite the evidence in support of using RT in this setting, the decision to
use it must take into account the side effects associated with treatment. There have been multiple
reports of acute and late toxicities after post-operative radiation therapy in prostate cancer.
Overall, RT appears to be well-tolerated in patients undergoing ART and SRT, and lessons drawn
from patients undergoing ART are therefore also broadly applicable to SRT.
In the SWOG 8794 study, no patients had to interrupt their RT secondary to side effects,
although grade 2 or greater complications were more common in the ART group than in the
observation arm (23.8% vs 11.9%, respectively; P = .002) [50]. Urethral strictures (17.8% vs
9.5%; P = .11), and rectal complications (3.3% vs 0%; P = .02) were the most frequent toxicities.
In a companion health-related QOL study, 217 of 425 SWOG 8794 patients completed a
questionnaire at baseline, 6 weeks, 6 months, and annually for 5 years [109]. The 6-week
assessment was included to record side-effects at their peak at the end or RT. Not surprisingly,
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patients being treated with RT had a greater likelihood of a decline in bowel QOL at the end of
RT as compared to the observation arm, but after 2 years, there was no significant difference
between the two groups in bowel QOL. With respect to genitourinary QOL, patients in the ART
arm experienced significantly more urinary urgency than those in the observation arm. However,
there was no statistically significant difference in erectile dysfunction (ED), but given that the
SWOG trial was performed prior to adoption of nerve sparing RP, > 90% of patients in both the
ART and observation arms had severe ED, limiting the ability to comment on the effect of RT on
erectile function in this patient population. Most noteworthy was that although global healthrelated QOL was worse in the ART group initially, it became similar by year 2, and at 5 years,
patients in the ART group reported an overall better QOL compared to those in the observation
arm. This is not surprising when taking into account the increased risk for metastasis and death as
well as the burden of salvage and hormonal therapies among the patients in the "wait-and-see"
arm.
In EORTC trial 22911, radiation treatment was interrupted as a result of toxic effects in
3.1% of patients, consisting of diarrhea, urinary frequency, proctitis, cystitis and anal pain [49].
Grade 2 or 3 late effects were significantly more numerous in the ART arm (P = .0005), but grade
3 toxicities were uncommon, with a 5-year rate of 2.6% in the observation arm and 4.2% in the
ART arm (P = .0726). No grade 4 or higher late toxic effects were reported. In comparison to the
EORTC 22911 and SWOG 8794 trials, the patients in the ARO 96-02/AUO AP 09/95 study had a
significantly lower rate of severe (grade 3 and higher) toxicities at only 0.3% [51]. This relatively
low rate of complications is likely due to the use of three-dimensional treatment planning, which
is known to reduce acute and late toxicities for RT for prostate cancer.
In addition to the toxicity data from these randomized ART trials, there have been several
assessments of complications following SRT. In a phase II prospective study by Pearse et al., 75
patients with biochemical relapse or local recurrence after RP were evaluated for acute and late
42

complications after SRT and 2 years of ADT [110]. Twelve percent of patients had
gastrointestinal (GI) dysfunction and 40% had genitourinal (GU) dysfunction prior to receiving
RT. Median follow-up was 45.1 months. No patients interrupted treatment secondary to side
effects. Overall, 94% of patients experienced acute complications, but grade 3 toxicities were rare
and the cumulative incidences for severe GI and GU toxicities were 1.6% and 2.8% at 36 months,
respectively. There were no late grade 4 complications.
Patients with preexisting GU dysfunction and acute GU toxicity were more likely to have
persisting late GU toxicity. In addition, the more severe the acute GU toxicity, the more likely it
was to persist. Peterson et al. reported on late toxicities (those occurring more than 90 days after
completion of radiation treatment) in 308 postprostatecomy patients who had undergone salvage
therapy [111]. In the study, radiation dose ranged from 54.0 to 72.4 Gy with a median dose of
64.8 Gy and was given in 1.8-2.0 Gy fractions. Median follow-up from the end of treatment was
60 months. Thirteen percent of patients reported late complications, but only an estimated 0.7%
(95% CI, 0.0–1.6%) of patients would experience severe (grade 3 or higher) toxicities by 5 years.
Among those reported in the study were grade 3 cystitis and grade 4 rectal complications. These
results are consistent with those of other reports, including data from the three recently
randomized trials on ART.
Finally, as mentioned previously, Feng et al. reported on 959 patients who received ART
or SRT, with a median dose of 64 Gy [64]. At 5 years, grade 3 urinary complications were
observed in 1% of patients and grade 3 bowel complications were only seen in 0.3%, indicating
excellent tolerance to ART and SRT. Similar toxicity was seen in a series from UCSD [100] and
Germany [112] which showed resolution of acute urinary symptoms without grade 3 toxicity.
Long-term toxicity was rare, and health related QOL changes were minor in comparison to
baseline scores. Together, these studies support a low incidence of severe toxicities in patients
receiving RT after RP.
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The Effect of Post-operative Radiation Treatment on Sexual Functioning
Of particular concern for many men is the issue of erectile dysfunction after prostate
cancer treatment. Indeed, there have been many studies showing that men feel discouraged and
emasculated by this sexual dysfunction [113-116]. It can take erectile functioning 18 months to 2
years to recover after prostatectomy, and radiation may further damage vascular structures in the
penis [4, 117]. It is unknown whether receiving RT before healing completely from surgery
exacerbates the problem. In addition to avoiding overtreatment of patients, SRT has the benefit
over ART of allowing patients more healing time. Of course, this advantage must be weighed
against decreasing chances of efficacy if RT is postponed for too long [118].
Research on the post-surgical effects of RT on erectile functioning is in the beginning
stages and results are ambiguous. In the companion SWOG health-related quality-of-life study
described previously, there was no statistical difference in erectile dysfunction between the ART
and observation arms [109]. However, more than 90% of patients in both groups experienced
sexual side effects, and the ART group's erectile functioning was consistently lower. Although
not statistically significant, these results may suggest that RT exacerbates erectile dysfunction in
post-operative patients. In a study by Hu et al, men who received SRT after surgery had worse
sexual functioning than men who had surgery alone [119].
However, this study had several limitations in that it was not randomized, and patients
who received radiation treatment had higher risk features and a lower use of nerve-sparing radical
prostatectomy, as compared to the surgery-only group. Therefore, the lower erectile functioning
of the SRT group could actually be related to confounding factors. Formenti et al. reported on a
prospective study in which 94 (37%) of 255 patients received 45-54 Gy of ART after
prostatectomy [120]. Three years after surgery, there was no difference between the ART and
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observation groups with respect to sexual functioning. However, the strength of these results is
limited because higher radiation doses are delivered in current clinical practice.
Cost-Effectiveness of Post-Operative Radiotherapy After Radical Prostatectomy
In the past decade, considerable advances in planning and delivery of radiotherapy took
place in the form of IMRT, resulting in the delivery of higher doses and improved toxicity
profiles. Despite the tremendous gains these technologies may represent in terms of quality of life
and tumor control, they are also associated with significant healthcare costs. Given the American
government’s major policy priority to curtail the growth of healthcare costs, it is appropriate to
evaluate the cost-effectiveness of post-operative radiotherapy with this treatment modality.
Although a formal assessment on the cost-effectiveness of post-operative radiotherapy
has not been performed to date, it is worthwhile presenting the available information on costs and
quality of life that is relevant to treatment. Surprisingly, the most significant costs of advanced
disease are the indirect costs, such as income lost from missing work, loss of productivity due to
hospitalization, pain or disfigurement, as well as shortening of life years. Taking all cancers into
account, the annual costs in the United States of lost productivity due to sickness and lost
productivity due to early death are estimated to be $18.8 billion and $116.1 billion, respectively
[121].In addition to these losses are the direct medical costs associated with metastatic disease,
which is also accompanied by tremendous pain and a worse quality of life. In a study by
Schulman et al., anonymous patient-level data on health care utilization and cost was obtained on
396,200 cancer patients from the Thomson Medstat MarketScan research databases, and patients
with metastatic bone disease were matched to patient controls without metastatic bone disease. A
2-part linear regression model was subsequently used to estimate the incremental cost of
metastases, and they found that the cost of treating a prostate cancer patient with metastatic bone
disease ($56,281) is nearly three times that of treating a man with confined disease ($19,781)
[122].
45

In a different study by Zubek et al., the cost and utility of various prostate cancer treatments and
disease states were described [123]. In the analysis, costs were based on the year 2006, and
“utility” was a measure of patient preferences on a scale of 0–1, with death having a utility of 0
and perfect health having a utility of 1. Utility values were measured with the EQ-5 EuroQol
quality of life instrument [124] or obtained from the literature. IMRT after prostatectomy was
estimated to cost $27,080 and be associated with a utility of 0.909, whereas end-of-life-care was
associated with values of $30,000 and 0.6. The cost and utility for androgen suppression therapy,
which is more commonly used in patients who are not treated with ART, were $9000 and 0.74,
respectively. Considering the substantial costs and decreased quality of life associated with
metastatic disease, it is very likely that the most cost-effective approach to treatment of patients
with high-risk prostate cancer is the one that offers the best chances for progression-free survival.

As previously mentioned, results from the SWOG trial indicate that when treating
patients with ART, only 10 and 12 men need to be treated to prevent one metastasis and one
death, respectively. These outcomes are especially convincing since the use of androgen
suppression therapy in the observation group was almost twice that of the adjuvant treatment arm
and about one-third of patients in the observation group eventually underwent delayed SRT. The
acceptable NNT value depends on the type of medical scenario, although a NNT of

20 is

generally used to justify the majority of treatments [125-128]. To put the value of ART into
perspective, Bill-Axelson et al. found a NNT of 19 at 12 years when comparing radical
prostatectomy to watchful waiting in patients with localized prostate cancer [129]. If it is
recommended that this group of patients undergoes surgery and that other patient populations
receive chemotherapy with an even higher NNT, it should also follow that patients with high-risk
pathological features ought to receive ART for an even greater (1:12) chance of improving
survival.
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In addition, there are several studies indicating that salvage radiotherapy does not
significantly decrease health-related QOL [64, 100, 112].Therefore, with a conservative estimate
of a 4 year 40%–50% progression-free survival for selected patients who undergo salvage
radiotherapy compared to a 0–20% progression free probability, it is also easy to see that salvage
radiotherapy would be acceptable under the generally accepted $50,000/QALYcost-effectiveness
standard. To our knowledge, a formal study of the cost-effectiveness of salvage radiotherapy
compared to hormone therapy or best supportive care has not been performed.
Risk-Prediction Tools Can Improve Cost-Effectiveness of Salvage Radiotherapy PostProstatectomy In order to minimize costs and prevent overtreatment with SRT, it becomes
necessary to identify which patients would benefit from radiation post-prostatectomy.
Approximately two-thirds of men who do not receive treatment for PSA recurrence after radical
prostatectomy will develop metastatic disease within 10 years [63]. As local disease could be
successfully treated with SRT, one important question is whether biochemical failure represents
regional or disseminated disease. Currently, there is no imaging technique that is able to reliably
detect sites of local recurrence in patients with low PSA levels. However, endorectal coil
magnetic resonance imaging has recently emerged as a promising new technology to assess postsurgical patients who may have local failure. There are two major studies that have evaluated this
technology's accuracy in recognizing local tumor relapse sites. In Silverman et al., sagittal and
axial fat-saturated T2-weighted fast spin-echo images and axial T1-weighted unenhanced and
gadolinium-enhanced eMR images were obtained in a prospective study of 41 post-prostatectomy
patients [97]. They achieved a sensitivity and specificity of 100%, with biopsy-proven disease as
the standard. In a retrospective study by Sella et al., T1- and T2-weighted sequences (without
gadolinium administration) from 48 patients were reviewed, and a sensitivity of 95% and
specificity of 100% was achieved [98]. Taken together, these studies suggest that endorectal coil
MRI may be a useful risk-prediction tool when evaluating post-surgical patients for local
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recurrence of malignancy. Although promising in initial studies, endorectal coil MRI has not been
prospectively validated for pre-SRT risk stratification, or routinely adopted at this time.
A number of studies have looked at clinical features that may predict a favorable clinical
outcome with SRT. The reports from single-institutional studies with respect to prognostic
features have been Inconsistent. However, in a retrospective multicenter review by Stephenson et
al. of 501 patients, the features associated with progression after SRT were a Gleason score of 8
to 10, a pre-radiotherapy PSA level greater than 2.0 ng/mL, negative surgical margins, PSA
doubling time (PSADT) of 10 months or less, and seminal vesicle invasion [130]. Favorable
patients were defined as those without any of these poor prognostic factors, and 70% of favorable
patients remained progression-free 4 years after SRT.
However, Stephenson et al. also revealed that certain patients with adverse features such
as high-grade disease or rapid PSADT may still benefit from SRT. For instance, when treatment
was given with PSA still < 2.0, if a patient had a rapid PSADT (<10 months), positive surgical
margins, and Gleason scores between 4–7, 4-year progression-free survival (PFP) was 64%. For
patients with Gleason 8-10 disease, but with a PSA < 2.0, positive surgical margins, and PSADT
> 10 mos, 4-year PFP was 81%. These results suggest that if a patient elected to not receive ART
in the immediate post-operative setting, then the benefit of SRT is likely greater even in the
setting of higher risk features if SRT is administered upon first sign of biochemical recurrence.
Nomograms have been designed to predict the outcome of SRT based on several patient
characteristics. In a separate study by Stephenson et al., they developed such a model using
multivariable Cox regression analysis and a multi-institutional cohort of 1,540 patients [67]. The
nomogram had a concordance index of 0.69. They found several features that should be taken
into account when predicting the 6-year-progression-free probability after SRT in postprostatectomy patients. These included PSA level < 2.0 ng/mL, Gleason score of 7 or less, PSA
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doubling time greater than 10 months, positive surgical margins, androgen-deprivation therapy
before or during SRT, and the absence of lymph node metastasis. This nomogram has been
externally validated by Moriera et al. [131]. The validation study involved 102 patients from the
Shared Equal Access Regional Cancer Hospital (SEARCH) database who were treated with SRT
for PSA failure after surgery. Even though the cohort was composed of lower-risk patients as
compared to the original series, the overall concordance index of the Stephenson nomogram was
reasonable, at 0.65. These authors also found that though the nomogram successfully predicted
failure at the extremes of risk, it was less accurate in the intermediate groups. Negative surgical
margins and high preradiotherapy PSA level were the only nomogram variables that were
significantly linked to disease progression [131]. Although the Stephenson nomogram is the best
available prediction tool currently available to predict who will obtain long-term benefit from
SRT, there is still significant room for improvement in this risk-prediction model.
Conclusion
New evidence indicates that immediate treatment with ART, rather than watchful waiting, is
more appropriate for the patient with pathologically advanced disease because it can improve
cancer-specific and overall survival. While post-operative radiation may cause side effects,
evidence suggests that the overall long-term quality of life is improved in patients who are treated
immediately after surgery rather than monitored for disease recurrence with the possibility of
later treatment. In addition, numerous consensus guidelines exist to aid the physician in planning
treatment fields. Although prostate cancer treatment decisions should take into account patient
preferences, cost of treatment, and treatment-related side effects, we suggest that patients with
long life-expectancies and positive surgical margins or pathological T3 disease, as well as an
undetectable PSA, should see a radiation oncologist to discuss the possibility of entering a
clinical trial such as RADICALS that addresses the best possible timing of post-operative RT. If a
clinical trial is not available, it is the opinion of the authors that patients with the above
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mentioned high-risk pathologic features should undergo immediate adjuvant radiation therapy.
This recommendation is made with the acknowledgement that there is no level-1 evidence
favoring ART over delayed SRT in a patient who has been followed carefully and SRT initiated
at low levels of PSA.
Randomized controlled trials are necessary to fully determine the utility of dose escalation. We
anticipate the results from the RADICALS trial to answer further questions regarding the
comparison of immediate ART to early SRT following biochemical relapse, and the role of
hormone therapy.
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Figure 1. Schematic of patient likelihood of clinical benefit stratification framework
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Figure 2. Inclusion Criteria
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Table 1. Bivariate analysis of factors associated with receipt of curative therapy for lowand moderate-risk prostate cancer patients
Low risk

Age

Race

Marital status

Comorbidity

Life expectancy (years)

Year of diagnosis

N

%treated

67-69

8768

70-74

Moderate risk
N

%treated

79.1

5019

83.9

14716

74.1

8370

79.9

75-79

10918

57.1

7040

67.1

80-85

5120

27.1

4241

39.2

White

33954

66.0

20466

72.0

Black

3365

58.6

2568

59.8

Other

2203

50.1

1636

61.8

28808

68.1

17568

74.8

Not married

7763

57.4

5148

61.5

Unknown

2951

47.6

1954

49.9

0

22939

68.1

14141

72.5

1-2

13203

62.3

8173

69.9

≥3

3380

48.2

2356

55.6

<5

922

24.1

737

31.6

5-<10

15492

50.7

10747

60.0

10-<15

19269

74.2

10955

79.5

≥15

3839

80.7

2231

84.5

≥10

23108

75.3

13186

80.4

1996

2639

57.7

1252

66.9

1997

2835

61.8

1290

67.5

1998

2736

61.9

1154

70.7

Married

p-value

<.0001

<.0001

<.0001

<.0001

<.0001

p-value

<.0001

<.0001

<.0001

<.0001

<.0001

(all registries)
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Overall

1999

2729

64.7

1124

69.1

2000

5097

67.2

2210

68.1

2001

5325

66.4

2299

70.1

2002

5346

66.1

2301

69.7

2003

4096

63.2

2630

70.4

2004

4491

64.4

5209

70.9

2005

4228

65.3

5201

71.4

39522

64.4

24670

70.0

<.0001

0.0112
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Figure 3. Percent of prostate cancer patients receiving curative treatment, stratified by
risk category and life expectancy

Percent receiving curative therapy

Use of curative therapy according to life expectancy
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Overall

Life expectancy (years)
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Table 2. Odds ratios of low- and moderate-risk prostate cancer patients receiving curative
therapy by patient characteristics and risk group, unadjusted and adjusted for age, race,
marital status, comorbidity, risk category, and year of diagnosis

LOW RISK TUMOR
CHARACTERISTICS

Age

Adjusted

Unadjusted

Adjusted

Unadjusted

Adjusted

OR

OR

OR

OR

OR

OR

(95% CI)

(95% CI)

(95% CI)

(95% CI)

(95% CI)

(95% CI)

1.00

1.00

1.00

1.00

1.00

1.00

0.76

0.77

0.76

0.77

0.76

0.77

(0.71,
0.81)

(0.72,
0.82)

(0.70,
0.84)

(0.70,
0.85)

(0.72,
0.80)

(0.73,
0.81)

0.35

0.37

0.39

0.40

0.37

0.38

(0.33,
0.38)

(0.34,
0.39)

(0.36,
0.43)

(0.37,
0.44)

(0.35,
0.39)

(0.36,
0.40)

0.10

0.10

0.12

0.13

0.12

0.11

80-85

(0.09,
0.11)

(0.10,
0.11)

(0.11,
0.14)

(0.11,
0.14)

(0.11,
0.12)

(0.11,
0.12)

White

1.00

1.00

1.00

1.00

1.00

1.00

0.74

0.71

0.58

0.55

0.67

0.64

(0.68,
0.79)

(0.66,
0.77)

(0.53,
0.63)

(0.50,
0.60)

(0.64,
0.71)

(0.60,
0.68)

0.52

0.58

0.63

0.73

0.57

0.64

Other

(0.48,
0.57)

(0.53,
0.64)

(0.57,
0.70)

(0.65,
0.82)

(0.53,
0.61)

(0.60,
0.69)

Married

1.00

1.00

1.00

1.00

1.00

1.00

67-69

75-79

Black

Marital
status

FULL SAMPLE

Unadjusted

70-74

Race

MODERATE RISK
TUMOR
CHARACTERISTICS

63

0.63

0.71

0.54

0.61

0.60

0.67

(0.60,
0.67)

(0.67,
0.75)

(0.50,
0.58)

(0.56,
0.65)

(0.58,
0.63)

(0.64,
0.70)

0.43

0.47

0.34

0.37

0.39

0.42

Unknown

(0.40,
0.46)

(0.43,
0.51)

(0.31,
0.37)

(0.33,
0.41)

(0.37,
0.42)

(0.40,
0.45)

0

1.00

1.00

1.00

1.00

1.00

1.00

0.78

0.90

0.88

1.01

0.81

0.94

(0.74,
0.81)

(0.85,
0.94)

(0.83,
0.93)

(0.95,
1.08)

(0.78,
0.84)

(0.90,
0.97)

0.44

0.55

0.47

0.60

0.46

0.57

(0.41,
0.47)

(0.51,
0.60)

(0.43,
0.52)

(0.54,
0.66)

(0.43,
0.48)

(0.53,
0.60)

1.00

1.00

1.29

1.52

(1.25,
1.34)

(1.46,
1.58)

Not
married

Comorbidity

1-2

≥3

Risk group

Low

Moderate
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Figure 4. Percent of low- and moderate-risk prostate cancer patients receiving curative
therapy over time, stratified by life expectancy.
A

Low-risk cancer
Percent receiving curative therapy
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B

Moderate-risk cancer
Percent receiving curative therapy
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Note: Data reflective of the registries participating in SEER throughout 1996-2005, only.
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Appendix 1. Elixhauser conditions included in sample analysis
Condition
Congestive Heart Failure
Cardiac Arrhythmia
Valvular Disease
Pulmonary Circulation Disorders
Peripheral Vascular Disorders
Paralysis
Other Neurological Disorders
Chronic Pulmonary Disease
Diabetes Uncomplicated
Diabetes Complicated
Renal Failure
Liver Disease
AIDS/HIV
Lymphoma
Rheumatoid Arthritis/collagen
Coagulopathy
Weight Loss
Fluid and Electrolyte Disorders
Deficiency Anemia
Alcohol Abuse
Drug Abuse
Psychoses
Depression
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Appendix 2. Prostate cancer treatment billing codes.
Treatment

Code

Any form of radiation (including ICD-9 Procedure

92.2x

brachytherapy)

ICD-9 Diagnosis

V58.0, V66.1, V67.1

HCPCS

77261 – 77799; 55859, 55860, 55862, 55865,
76965, C1715-C1720, C2633-C2642, Q3001

0330-0339

Revenue center

Any prostate surgery

ICD-9 Procedure

60.3, 60.4, 60.5, 60.62, 60.69

HCPCS

55810, 55812, 55815, 55840, 55842, 55845,
55866, 55801, 55821, 55831

Note: The HCPCS codes C2643, C2698, C2699, and ICD-9 Procedure code 60.6 were also
investigated but not found within our sample.
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Part II
Table 3. Patient characteristics (n=223)

Category

Number of patients

Percent

Race
White

180

80.7%

Black

40

17.9%

Hispanic

1

0.45%

Asian / Other / Unknown

2

0.9%

6

73

32.7%

7

103

46.2%

8-10

47

21.1%

PSA < 4

10

4.5%

4 ≥ PSA < 10

121

54.3%

10 ≥ PSA < 20

62

27.8%

20 ≥ PSA

30

13.4%

T1b

2

0.9%

T1c

141

63.2%

T2a

42

18.8%

T2b

15

6.7%

T2c

6

2.7%

T3

17

7.7%

Favorable

44

19.7%

Gleason score

Pretreatment PSA

Clinical T stage

Prognostic Group*

68

Intermediate

106

47.5%

Poor

73

32.7%

3D conformal radiation + IMRT
boost

111

49.8%

IMRT alone

97

43.5%

Pelvic RT + IMRT boost

15

6.7%

Hormonal therapy

177

79.4%

No hormonal therapy

46

20.6%

Type of radiation

Adjuvant therapy

* Favorable prognostic group was defined as having a T1-T2a, Gleason score 6, and PSA < 10.
Intermediate risk was T2b-T2c, Gleason score 7, or PSA 10-20 ng/mL. High risk was defined as
T3, Gleason score 8-10, or PSA > 20.
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Figure 5. Biochemical Disease-Free Survival over time, stratified by cancer-risk group
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Table 4. Use of Adjuvant Therapy and Pelvic Therapy by prognostic group

Number
Receiving
Adjuvant
Hormone
Therapy
(percent)

Odds Ratio –
Likelihood of
Receiving
Adjuvant
Hormone
Therapy
[95% CI]**

P value**

Number
Receiving
Pelvic RT

Odds Ratio
–
Likelihood
of
Receiving
Pelvic RT
[95% CI]**

0

***

P value**

Prognostic group
Favorable
(n=44)

13/44
(29.5%)

1*

Intermediate
(n=106)

93/106
(87.7%)

17.1 [7.1 –
40.7]

<0.001

2/106
(1.9%)

1*

Poor (n=73)

71/73
(97.3%)

84.7 [18.0 –
397.8]

<0.001

13/73
(17.8%)

11.3 [2.551.6]

<0.001

*Reference values
** Calculated with logistic regression
*** Not calculated
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Table 5. Univariable and multivariable survival analysis – risk of biochemical disease free
survival (ASTRO-Phoenix Definition)

Category

Univariable Hazard
Ratio [95% CI]

Univariable
p-value****

Multivariable
Hazard Ratio
[95% CI]***

Multivariable
p-value****

0.68

Race
White

1*

1*

Black

0.61 [0.24-1.56]

0.50 [0.20-1.29]

Hispanic

**

**

Asian / Other /
Unknown

**

**

0.15

<0.0001

Gleason score
6

1*

7

0.94 [0.42-2.10]

8-10

4.41 [2.02-9.63]
0.091

Pretreatment PSA
PSA < 4

1*

4 ≥ PSA < 10

0.53 [0.15-1.83]

10 ≥ PSA < 20

1.09 [0.31-3.77]

20 ≥ PSA

1.33 [0.36 – 4.96]
0.024

Clinical T stage
T1c

1*

T2a

1.04 [0.47-2.27]

T2b

4.81 [2.13-10.9]

T2c

1.06 [0.14-7.91]

T3 – T4

1.50 [0.51-4.35]

Prognostic Group

0.0020
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Favorable

1*

1*

Intermediate

1.59 [0.54-4.75]

2.02 [0.58-7.08]

0.27

Poor

4.10 [1.42-11.88]

6.12 [1.63-23.01]

0.007

0.188

Type of radiation
3D conformal radiation
+ IMRT boost

1*

1*

IMRT alone

0.54 [0.27-1.07]

0.61 [0.30-1.23]

0.17

Pelvic RT + IMRT
boost

0.70 [0.16-2.96]

0.45 [0.10-1.96]

0.29

0.41

Adjuvant therapy
No Hormonal therapy

1*

1*

Hormonal therapy

1.39 [0.62-3.12]

0.56 [0.21-1.54]

0.264

* Reference value
** Numbers too small to meaningfully calculate
*** Multivariable model included prognosis, adjuvant therapy yes/no, race, and type of RT.
Gleason score, pretreatment PSA, and clinical T stage are taken into consideration for the
prognosis, and so were not included separately in the multivariable model.
**** Calculated by Cox proportional hazards analysis

73

Table 6. Acute and late toxicity

All

Genitourinary

Gastrointestinal

Acute Toxicity (From start of RT
to end of RT + 60 days)

Late Toxicity (Toxicity that
occurred > 60 days after
completion of RT)

Grade-3 – 12.1%

Grade-3 – 4.0%

Grade-4 – 0.45%*

Grade-4 – 0.9%***

Grade-2 – 30.0%

Grade-2 – 3.6%

Grade-3 – 7.6%**

Grade-3 – 0.45%

Grade-4 – 0%

Grade-4 – 0%

Grade-2 – 12.1%

Grade-2 – 4.0%

Grade-3 – 2.7%

Grade-3 – 1.3%

Grade-4 – 0%

Grade-4 – 0%

* One patient had a cardiac event unrelated to radiotherapy.
** This includes 5 patients with urethral or testicular pain requiring at least one episode of
narcotic use.
*** One patient had a cardiac event unrelated to radiotherapy, and one patient had abdominal
pain unrelated to radiation therapy.
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Table 7. High dose prostate irradiation - Toxicity

Author /
Institution /
Nature of study

N

Dose

Type of
radiation
technique

Zelefsky et al. /
MSKCC /
Retrospective[13]

1100

All patients
(64.8-86.4
Gy)

3DCRT +
IMRT

GI or GU Acute
Toxicity

GI or GU Late
Toxicity

GI Grade-3 – 1%
GI Grade-4 – 0.1%

GU Grade-3 – 1.5%
GU Grade-4 – 0%
61

81 Gy

3DCRT

GI Grade-2 – 12%
GI Grade-2 – 2%

189

81 Gy

IMRT

GI Grade-3 – 2%
GI Grade-3 – 0.5%

40

86.4 Gy

IMRT

GI Grade-2 – 5%
GI Grade-3 – 0%

GU Grade-2 – 20%
GU Grade-3 – 0%
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Zelefsky et al. /
MSKCC /
Retrospective[21]

561

81 Gy

GI Grade-2 – 1.5%

IMRT

(Rectal bleeding)

GI Grade-3 – <1%
(Defined as rectal
bleeding requiring 1 or
more transfusions or 1
cauterization
procedure)

GI Grade-4 – 0%

GU Grade 2 – 9%
(Chronic urethritis
requiring medication
for symptom control)

GU Grade-3 – 3%
(Defined as urethral
stricture requiring
dilation)

Zelefsky et al. /
MSKCC /
Retrospective[21]

478

86.4 Gy

IMRT

GI Grade 2 – 8%

GI Grade 2 – 3%

GI Grade 3 – 0%

GI Grade 3 – 0.4%

GI Grade 4 – 0%

GI Grade 4 – 0%

GU Grade 2 – 22%

GU Grade 2 – 13%

GU Grade 3 – 0.6%

GU Grade 3 - <3%

GU Grade 4 – 0%

GU Grade 4 – 0%
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Kuban et al. /
MDACC /
Prospective,
Randomized[15]

150

70 Gy

3DCRT

Crude 10-year rate:
GI Grade-3 – 1%
GI Grade-4 – 0%

GU Grade-3 – 5%
GU Grade-4 – 0%
151

78 Gy

3DCRT

Crude 10-year rate:
GI Grade-3 – 7%
GI Grade-4 – 0%

GU Grade-3 – 4%
GU Grade-4 – 0%
Zietman et al. /
MGH and Loma
Linda /
Prospective,
Randomized[14]

196

195

Michalski et al. /
RTOG 9406 /
Prospective
phase I-II[22]

70.2 Gy

79.2 Gy

3DCRT +
Proton

3DCRT +
Proton

GI Grade-3: 1%

GI Grade-3: 1%

GI Grade-4: 0%

GI Grade-4: 0%

GU Grade-3: 1%

GU Grade-3: 2%

GU Grade-4: 0%

GU Grade-4: 0%

GI Grade-3: 0%

GI Grade-3: 1%

GI Grade-4: 0%

GI Grade-4: 0%

GU Grade-3: 2%

GU Grade-3: 1%

GU Grade-4: 0%

GU Grade-4: 0%

112

68.4 Gy (1.8
Gy/Fx)

3DCRT

GI or GU Grade 3+:3-6%

300

73.8 Gy (1.8
Gy/Fx)

3DCRT

GI or GU Grade 3+: 2-4%

167

79.2 Gy (1.8
Gy/Fx)

3DCRT

GI or GU Grade 3+: 6%
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De Meerleer et
al. / Belgium /
Retrospective[20]

256

74 Gy (2
Gy/Fx)

3DCRT

GI or GU Grade 3+: 7-9%

220

78 Gy (2
Gy/Fx)

3DCRT

GI or GU Grade 3+: 9-12%

114

72-78 Gy*

IMRT

GI Grade-3: 0%
GI Grade-4: 0%

GU Grade-3: 7%
GU Grade-4: 0%
De Meerleer et
al. / Belgium /
Retrospective[17]

133

72-74 Gy**

IMRT

GI Grade-3: 1%
GI Grade-4: 0%

GU Grade-3: 3%
GU Grade-4: 0%
Liauw et al./
University of
Chicago/
Retrospective[24]

130

74-76
Gy***

IMRT

GI Grade-2:38%

GI Grade-2: 9%

GI Grade-3:0%

GI Grade-3: 5%

GI Grade-4:0%

GI Grade-4: 0%

GU Grade-2: 45%

GU Grade-2: 31%

GU Grade-3: 2%

GU Grade-3: 6%

GU Grade-4: 0%

GU Grade-4: 0%
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Martin et
al./University of
Toronto/
Prospective[25]

92

60 Gy in 20
fractions
over 4
weeks

IMRT
Hypofractionated

GI Grade-2: 11%

Actuarial

GI Grade-3: 1%

GI Grade-2: 5.1%

GI Grade-4 0%

GI Grade-3: 1.2%
GI Grade-4 0%

GU Grade-2: 25%
GU Grade-3: 0%

GU Grade-2: 10%

GU Grade-4: 0%

GU Grade-3: 0%
GU Grade-4: 0%

Raldow et al.
(This study) /
Yale School of
Medicine /
Retrospective

228

75.6 Gy

3D+ IMRT

GI Grade 2: 12.1%

GI Grade 2: 4.0%

GI Grade 3: 2.7%

GI Grade 3: 1.35%

GI Grade 4: 0%

GI Grade 4: 0%

GU Grade 2: 30.0%

GU Grade 2: 3.6%

GU Grade 3: 7.6%

GU Grade 3: 0.45%

GU Grade 4: 0%

GU Grade 4: 0%

* Dose reported here as maximum rectal dose, given in 36-38 fractions. Median prostate PTV
dose was 74-78 Gy.
** Dose reported here as maximum rectal dose, given in 36-37 fractions. Median prostate PTV
dose was 74-76 Gy.
***Of 130 patients, 36 low-risk patients were treated with 74 Gy; and 69 intermediate-risk and 25
high-risk patients were treated with 76 Gy
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Table 8. High dose prostate irradiation – Outcomes

Author /
Institution /
Nature of study

N

Zelefsky et al. /
MSKCC /
Retrospective[13]

365

Dose

64.8 Gy –
70.2 Gy

Type of
radiation
technique
3DCRT

BDFS (Except where marked otherwise)
Favorable

Intermediate

Poor

a

a

a

*

5 year - 77%

193

75.6 Gy

*

5 year - 50%

5 year - 21%
(95% CI +/- 4%)
a

3DCRT+
IMRT

*

*

5 year - 43%
(95% CI +/- 4%)
65

81.0 Gy

a

3DCRT +
IMRT

*

5 year - 67%
(95% CI +/- 4%)
Zelefsky et al. /
MSKCC /
Retrospective[21]

561

Zelefsky et al. /
MSKCC /
Retrospective[21]

478

Kuban et al. /
MDACC /
Prospective,
Randomized[15]

150

Kupelian et al. /
Multi-institutional
/
Retrospective[89]

151

1061

264

81 Gy

86.4 Gy

70 Gy

78 Gy

< 72 Gy

≥ 72 Gy

IMRT

IMRT

3DCRT

3DCRT

EBRT

EBRT

b

**

b

**

b

**

8 year – 89%

8 year – 78%

8 year – 67%

b

b

b

**

**

**

5 year – 99%

5 year – 79%

5 year – 72%

c

c

c

**

**

**

8 year – 63%

8 year – 76%

8 year – 26%

c

c

c

**

**

**

8 year – 88%

8 year – 86%

8 year – 63%

(p=0.042)

(p=0.36)

(p=0.004)

d

d

d

*

*

*

5 year – 75%

5 year – 63%

5 year – 38%

d

d

d

*

*

*

5 year – 79%

5 year – 72%

5 year – 46%

(p=0.359)

(p=0.026)

(p=0.126)
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Kupelian et al. /
Cleveland Clinic /
Retrospective[85]

321

307

< 72 Gy

≥ 72 Gy

EBRT

EBRT

e

***

107

≤ 66 Gy

***

8 year – 48%

8 year – 28%

e

e

***

8 year - 86%
Valicenti et al. /
RTOG / Pooled
results from
prospective,
randomized
trials[19]

e

***

8 year – 61%
f

EBRT

****

(Gleason 8-10)
5 year – 61%
10 year – 31%

331

> 66 Gy

f

EBRT

****

(Gleason 8-10)
5 year – 71%
10 year - 46%
(p=0.041)
Hanks, et al. / Fox
Chase /
Retrospective[27]

34

< 72.5 Gy

3DCRT

g

*

5 year – 77%
(Favorable and
PSA < 10)
191

≥ 72.5 Gy

3DCRT

g

*

5 year – 89%
(Favorable and
PSA < 10)
(p=0.11)
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67

35

< 76 Gy

3D

g

g

5 year – 70%

5 year – 51%

(Unfavorable and
PSA < 10)

(Unfavorable and
PSA ≥ 10)

*

*

5 year – 72%
56
(Favorable and
PSA 10 – 19.9)

46

36

≥ 76 Gy

3D

g

g

5 year – 92%

5 year – 82%

(Unfavorable and
PSA < 10)

(Unfavorable
and PSA ≥ 10)

(p=0.0092)

(p=0.0054)

*

*

5 year – 86%
(Favorable and
PSA 10 – 19.9)

52

(p=0.10)

Zietman et al. /
MGH and Loma
Linda /
Prospective,
Randomized[14]

197

195

De Meerleer /
Belgium /
Retrospective[20]

133

70.2 Gy

79.2 Gy

h

74-76 Gy

3D +
Proton

e

5 year – 60.1%

5 year – 63.4%

3D +
Proton

e

e

IMRT

*

*

e

*

*

5 year – 80.5%

5 year – 79.5%

(p<0.001)

(p=0.03)

*

*

*

5 year – 100%

5 year – 94%

5 year – 74%
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Liauw et al./
University of
Chicago/
Retrospective[24]

130

Martin et
al./University of
Toronto/
Prospective[25]

92

Valicenti et al. /
RTOG 94-06 /
Prospective[19]

920

74-76 Gy

IMRT

b

**

b

**

b

**

4 years- 97%

4 years- 94%

4 years- 87%

60 Gy in
20
fractions
over 4
weeks

IMRT
Hypofractionated

**

**

**

3-year – 100%

3-year – 85%

3-year – 71%

> 73.8 Gy

3D CRT

RT alone

RT alone

RT alone

5 year – 85%

5 year – 82%

5 year – 69%

RT + Hormone
therapy (HRT)

RT + HRT

RT + HRT

5 year – 76%

5 year – 69%

5 year – 83%
RT + Long term
hormone therapy
(LHRT)
5 year – 71%

Raldow et al. /
Yale /
Retrospective
(Current study)

223

75.6 Gy

3D +
IMRT

b

**

5 year – 92.1%

b

**

5 year – 83.5%

b

**

5 year – 59.0%

* ASTRO definition
** Phoenix definition (PSA Nadir + 2)
*** Definition of failure is any PSA > 0.5 ng/mL that is not clearly decreasing
**** 5 and 10 year disease specific survival defined as death due to prostate cancer
Favorable group was defined as having the following three indicators: (1) PSA ≤ 10, (2)
Gleason Score ≤ 6, and (3) stage T1 to T2. Intermediate defined as the absence of one of the three
indicators, and poor prognostic group defined as the absence of two or more indicators.
a
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Favorable defined as PSA < 10, Gleason score ≤ 6, and stage T1 to T2a, intermediate defined as
clinical stage T2b or T2c, Gleason score of 7, or pretreatment PSA 10 to 20, and poor defined as
clinical stage T3a or higher, Gleason score ≥ 8, or pretreatment PSA > 20 ng/ml.
b

Favorable defined as PSA ≤ 10, Gleason Score ≤ 6, and stage T1 to T2a, poor defined as
Gleason score ≥ 8, PSA > 20, or T3, and intermediate patients all others.
c

Favorable defined as PSA ≤ 10, Gleason Score ≤ 6, and stage T1b to T2a, poor defined as
Gleason Score 8-10 or PSA > 20, and intermediate patients all others. T1a and T3 patients were
not included.
d

Favorable defined as PSA ≤ 10, Gleason score ≤ 6, and stage T1 to T2a. Unfavorable is defined
as all others.
e

f

Unfavorable defined as Gleason score 8-10.

Favorable defined as Gleason score ≤ 6, stage T1 – T2a, and no perineural invasion.
Unfavorable is all others.
g

h

Dose reported here as median prostate PTV dose.
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Table 9. Comparison of biochemical relapse-free survival in the ART and observation arms as
reported from the three randomized controlled trials.

Followup
EORTC 22911[49]

5 years

bRFS in ART arm
Overall: 74%
Undetectable (
PSA: 78.8%

SWOG 8794[132]

10.6 years

ARO96-02/AUO AP
09/95 [51]

5 years

bRFS in observation arm
Overall: 52.6%

0.2 ng/mL)

Undetectable (
PSA: 59.6%

0.2 ng/mL)

Detectable PSA: 37.6%

Undetectable (
PSA: 65.1%
Undetectable (
PSA: 72%

Undetectable (
PSA: 36%
Undetectable (
PSA: 54%

0.1 ng/mL)

pValue
p < 0·00
01
p < 0·00
01
p < 0·00
01

0.48

Detectable PSA: 62.6%
0.4 ng/mL)

Hazard
ratio

0.4 ng/mL)
0.1 ng/mL)

0.50
0.46
0.43

p<.001

0.53

p = .001
5
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